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Abstract  
Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest in the world. The 
World Health Organization currently estimates that worldwide, cervical cancer will kill more 
than 443,000 women per year by 2030, of which 90% of deaths are predicted to occur in 
SSA. The Human Papillomavirus (HPV) vaccine provides primary protection against the 
most common cancer-causing strains of HPV that are responsible for cervical cancer. Over 
the last five years, there has been a slow increase in the number of African countries that 
have introduced the HPV vaccine via demonstration and pilot projects, and a minority of 
African countries that have incorporated the HPV vaccine into their National Immunisation 
Programmes. As part of this systematic review, a literature review was conducted and 
revealed that research has been conducted on top-down barriers and facilitators to HPV 
vaccine uptake and have found that poor health system capabilities, inaccessibility to medical 
care, low cervical cancer screening levels, inadequate infrastructure, finances, and health 
worker training are significant systemic barriers to HPV vaccination success in SSA. Little 
research has been conducted on demand-side or end-user perspectives of, and decisions 
around, the HPV vaccine. In order to complement existing research, and inform current and 
future implementation approaches, this qualitative systematic review explored stakeholder 
understandings of the HPV vaccine in SSA. This review searched the following databases: 
Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic 
Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, 
SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) 
and found a total of 259 articles. Of these, 31 articles met the inclusion and exclusion criteria 
and were included in the review. Braun and Clarke’s six step process for conducting a 
thematic analysis was used for analysis and studies were assessed for quality using the 
Critical Appraisal Skills Programme (CASP) checklist. Three major themes emerged from 
the thematic analysis: knowledge is intertwined with misinformation; fear shapes 
contradictory perceptions about the HPV vaccine; and social norms and gender dynamics are 
relevant factors in how stakeholders understand the HPV vaccine in SSA. This review 
iterates the importance of first working with communities to gauge understandings of the 
HPV vaccine, before trying to implement change through education, sensitization and 
behavior change.  
Keywords: Human Papillomavirus (HPV); Human papillomavirus vaccine (HPV vaccine); 
Sub-Saharan Africa (SSA); thematic analysis; systematic review; qualitative research 
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Part A: Protocol 
 
Background to Protocol  
 
The human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
among men and women world-wide (CDC, 2016a; WHO, 2018). HPV is predominately 
transmitted through vaginal and anal sex, though it can also be transmitted through oral sex 
(WHO, 2018). The most common agents of transmission include direct contact with infected 
genital skin, mucous membranes, and bodily fluid, likely after the onset of first sexual 
activity (CDC, 2016a; WHO, 2017). Most sexually active men and women are infected or 
repeatedly infected with HPV throughout the life course, likely unknowingly, since 70-90% 
of HPV cases are asymptomatic and spontaneously resolve within one to two years (WHO, 
2018). HPV types are designated as ‘high’, ‘intermediate’ or ‘low-risk’ types depending on 
their oncogenicity or cancer-causing strength (WHO, 2017, 2018). Although the majority of 
HPV cases are asymptomatic and do not cause health issues, roughly 10% of HPV infections 
with intermediate to high risk types of HPV infection do not naturally regress, and instead, 
remain undetected in the reproductive tract initiating persistent infection (WHO, 2018). 
Depending on the type of HPV, persistent infection can cause a spectrum of health outcomes 
that range in severity from genital warts, to cases of respiratory papillomatosis, and to more 
severe cases of HPV-related cancer in men and women alike (WHO, 2017, 2018). This 
analysis will specifically focus on cervical cancer, the most common clinical consequence of 
persistent HPV infection (WHO, 2017, 2018).  
 
HPV is comprised of over two hundred strains of ‘papillomavirus isolates’ commonly known 
as HPV ‘types’ that derive from the papovaviridae family (Sanclemente & Gill, 2002; WHO, 
2017). A precancerous lesion, coupled with persistent infection with high risk types of HPV 
(most commonly type 16 and 18) will likely initiate the formation of invasive carcinomas that 
over time progress to cancers of the cervix, vulva, vagina, anus, penis, oropharynx, head, and 
neck that affect both men and women respectively (CDC, 2016b; WHO, 2018). Oncogenic or 
high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, and 58) are associated with cervical, vulvar, 
vaginal, and anal cancers, and non-oncogenic or low-risk types (6, 11, 40, 42, 43, 44, and 54) 
are associated with genital warts (Lacombe-Duncan et al., 2018; Munoz et al., 2003; 
Sanclemente & Gill, 2002). The most common strains associated with genital warts are HPV 
types 6 and 11, which are responsible for approximately 90% of these lesions (Braaten & 
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Laufer, 2008). The most common and oncogenic of all HPV types is type 16, accounting for 
almost half of all cervical cancers alone, and together with HPV 18, account for 
approximately 70% of cervical cancers (Clifford et al., 2003; Kidd et al., 2017).  
  
HPV-related cancers are preventable due to the licensure of prophylactic HPV vaccines, first 
approved in 2006 by the Federal Drug Administration (FDA) in the United States (Kidd et 
al., 2017). There are currently three vaccines that target the most common types of HPV, all 
of which are considered to be equally effective (WHO, 2018). Current recommendations for 
administration of the HPV vaccine is prior to the onset of sexual activity for both adolescent 
males and females, ideally between the ages of 9-14 years old, and in theory, prior to initial 
exposure to HPV (WHO, 2018). 
 
National programs maintaining at least a 50% coverage or 2 or 3 dose schedules “have 
demonstrated a dramatic impact on population level HPV prevalence, persistent HPV 
infection, genital warts, and cervical intraepithelial neoplasia” (Gallagher et al., 2018). Since 
the HPV vaccines have been introduced, over 80 countries in the world have initiated HPV 
vaccination programs, the majority of which are high income countries (HIC) or upper-
middle income countries (UMIC) (Gallagher et al., 2018). Low-income countries (LIC) and 
low-middle income countries (LMIC) have faced historical, programmatic, and residual 
barriers to HPV vaccination delivery, accessibility and coverage when compared to middle-
income and high-income counter parts (Gallagher et al., 2018). Gavi, the Global Alliance for 
Vaccines and Immunizations, has been integral in scaling up HPV vaccine support and 
accessibility in LIC/LMICs through provision of demonstration projects and national project 
initiatives for eligible countries (Gallagher et al., 2018). Although there has been a lag in 
HPV vaccine introductions in LIC/LMIC since licensure, “the pace since the HPV vaccine 
became accessible in these countries, given the barriers to introduction, is encouraging” 
(Gallagher et al., 2018; WHO, 2018). Africa, and more specifically Sub-Saharan Africa 
(SSA), bears the highest burden of cervical cancer world-wide, and requires high rates of 
HPV vaccine uptake in order to curb the cervical cancer epidemic through primary 
prevention (L. Bruni et al., 2019 ; WHO, 2017 ).  
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Introduction  
 
The global burden of HPV disproportionately affects Africa, evident in rates of penile and 
cervical cancers being amongst the highest in the world (Olesen et al., 2014; WHO, 2017). 
Cervical cancer accounts for 22% of all newly diagnosed cancers on the continent of Africa 
and the age-standardized mortality rates are 7 to 10 times higher in Africa than in North 
America, Australia, New Zealand, and Western Asia (Saudi Arabia and Iraq) (Bray et al., 
2018). Globally, Africa has the highest regional incidence and mortality rates from cervical 
cancer and was the leading cause of death in women in Africa in 2018 (Bray et al., 2018). 
The Report on Human Papillomavirus and Related Diseases in Africa estimated that in 2018 
there were 81,687 deaths and 119,284 incident cases of cervical cancer, the vast majority of 
which (111,632 incident cases) occurred in Sub-Saharan Africa (L. Bruni et al., 2019 ). In 
2018, the most elevated rates of cervical cancer incidence and mortality were seen in 
Southern Africa (e.g., Swaziland), Eastern Africa (Malawi and Zimbabwe) and Western 
Africa (Guinea, Burkina Faso, and Mali) (Bray et al., 2018). Stark differences between 
cervical cancer morbidity and mortality between HICs and LMICs are attributable to a 
variety of factors, including but not limited to, differences in population-based screening, 
HPV vaccine coverage at the population level, health care system efficiencies and 
epidemiological differences (Abdullahi et al., 2014; Black & Richmond, 2018; WHO, 2018). 
 
 The introduction of prophylactic HPV vaccines have made primary prevention of cervical 
cancer possible in places that bear even the greatest burden of the epidemic (Black & 
Richmond, 2018). In 2006, the first licensed HPV vaccination was the quadrivalent vaccine, 
followed by the addition of the bivalent vaccine and nonavalent vaccine in 2007 and 2014 
respectively (WHO, 2017). The vaccines are intended to be administered before the 
recipients onset of sexual activity and therefore prior to exposure to HPV (WHO, 2018). 
Although all three of the HPV vaccines have become available for adolescent males and 
females, the uptake of the HPV vaccine in Africa and SSA has been specifically targeted at 
adolescent females in order to most cost-effectively curb the cervical cancer epidemic in 
countries heavily impacted by HPV, yet often under resource constraint countries (L. Bruni et 
al., 2019 ; WHO, 2017, 2017 2019). As of June 2018, the HPV vaccine has been licensed in 
National immunisation programmes in over 100 countries world-wide, nine of which are in 
SSA: Botswana (2015), Lesotho (2012), Rwanda (2011), Sao Tome and Principe (2016), 
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Senegal (2016), Seychelles (2014), South Africa (2014), Uganda (2012), and Mauritius 
(2016) (Black & Richmond, 2018; L. Bruni et al., 2019 ; Chido-Amajuoyi et al., 2019; 
Gallagher et al., 2018). Over twice as many Sub-Saharan African countries are recently or 
currently undergoing pilot programmes for HPV vaccination (Black & Richmond, 2018).  
 
Despite HPV vaccination programs being introduced and steadily implemented in Sub-
Saharan African countries since 2011, cervical cancer incidence in women in SSA remains 
abnormally high when compared to the rest of the world (Black & Richmond, 2018). 
Previous mixed methods and qualitative systematic reviews in Africa have more generally 
examined knowledge and awareness of the HPV vaccine, as well as HPV vaccine willingness 
and acceptability. Such reviews concluded that although there are generally low to moderate 
levels of knowledge and awareness of the HPV vaccine, there is a notable understanding of 
the importance of the HPV vaccine. This has led to high levels of willingness and 
acceptability, as well as positive attitudes and practices towards HPV vaccination, however 
the disconnect behind historically low HPV vaccination uptake rates in Africa persists 
(Abdullahi et al., 2014; Melissa S. Cunningham et al., 2014; Perlman et al., 2014). Research 
into ‘supply-side’ barriers and facilitators of HPV vaccination in SSA has shown that top-
down factors have slowed the HPV vaccines’ success including poor service access, 
inadequate infrastructure and finances, limited health worker training, competing morbidities, 
vaccine cost, inaccessibility to medical care, and cold chain capacity constraints (Black & 
Richmond, 2018; Perlman et al., 2014).  
 
Adolescents, parents and care givers, teachers and health care workers and political, 
community and religious leaders have been identified as key populations of stakeholders that 
are not only relevant to HPV vaccination, but also vital to its success, as they create a 
required ‘demand’ for the HPV vaccine (Abdullahi et al., 2014; Marshall et al., 2018; 
Newman et al., 2018; Perlman et al., 2014; Radisic et al., 2017). In this review, relevant 
demand-side stakeholders will therefore be considered end-users or beneficiaries of the HPV 
vaccine, thus including adolescent recipients, as well as stakeholders who contribute to and 
shape decision-making around the HPV vaccine at the interpersonal and communal level. The 
literature may present other demand-side stakeholders who are influential on the demand side 
of the HPV vaccine and the review will recognize and incorporate such stakeholders with 
justification for inclusion, using a reflexive process for transparency. Data on HPV vaccine 
coverage in Sub-Saharan African countries is limited, but from available data, there is a lack 
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of qualitative exploration of how demand-side stakeholders understand the HPV vaccine in 
SSA.  
 
Review Questions  
 
Main Research Question:  
This systematic review aims to utilize relevant literature to provide a contextual 
understanding of how demand-side stakeholders understand and perceive of the HPV vaccine 
in SSA. The main research question is therefore “How do relevant demand-side stakeholders 
in SSA understand the HPV vaccine?” 
 
Subsidiary research questions 
 
• How are understandings of the HPV vaccine shaped by experiences, perceptions, 
knowledge, attitudes, and beliefs in SSA?  
• What specific contextual factors in SSA contribute to understandings around the HPV 
vaccine? 
 
Objectives of the review questions 
 
The objective of this systematic review is to identify, organize, and analyse qualitative data 
on  ‘demand-side’ perceptions, understandings and experiences of the HPV vaccine in SSA 
using a thematic analysis approach. If the qualitative data proves to be sufficiently available 
and viable in quality and quantity, this review will conduct a thematic analysis to highlight 
emerging themes around the HPV vaccine in SSA that can potentially contribute to the pool 
of HPV vaccination knowledge in terms of what works, for whom, it what contexts, and why 
(Booth et al., 2013).  
 
The key objectives are:  
1. To identify, appraise and synthesize qualitative research evidence on how 
stakeholders understand, experience and perceive the HPV vaccine in SSA.   
2. To identify and generate themes of relevant factors of influence on stakeholder 
understandings of HPV. 
3. To identify hypotheses for subsequent consideration and assessment of current and 
future HPV vaccination roll out strategies in SSA.  
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Identifying, appraising and synthesising the qualitative evidence of stakeholders 
understandings, experiences, and perceptions of the HPV vaccine in SSA will compliment 
reviews on HPV vaccine effectiveness and help improve understandings of the barriers and 
facilitators of successful implementation of HPV vaccination strategies in SSA (Odendaal et 
al., 2015).  
 
 
Methodology 
 
This qualitative systematic review is in fulfilment of the mini-dissertation component of the 
Master of Public Health at the University of Cape Town. This review will therefore be led by 
one lead author and reviewer (CD) with oversight guidance from two supervisors (AS & SC). 
The APA style of referencing will be used. 
 
Literature search strategy  
 
This systematic review will utilize qualitative literature to assess understandings of the HPV 
vaccine from identified key populations of adolescents, care givers, teachers, health care 
providers, political, community and religious leaders, along with any other relevant 
stakeholder (on the demand-side of the HPV vaccine) that the literature may speak to. 
Exploring the understandings, perspectives, and experiences stakeholders will provide a 
consensus of the status of the HPV vaccine in SSA, contributing to the greater understanding 
of the HPV-related disease epidemic in SSA.  
 
Optimal searches for comprehensive systematic reviews should include searches from 
Embase, MEDLINE, Web of Science, and Google Scholar as a minimum requirement for a 
systematic review (Bramer et al., 2017). This review will search the following relevant 
databases: Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, 
Academic Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, 
SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL). 
After abstract screening is complete, the reference lists of included articles will also be 
searched to see if additional articles meet the outlined inclusion criteria. Due to time, 
resource and language constraints, grey literature and non-English articles will not be 
included in this review. Background information on eligible studies will be maintained 
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(Appendix B).  
 
Initial key words have been selected based off a preliminary search of the literature, the aims 
of the systematic review, synonyms in the area of a study and the development of a 
comprehensive search strategy with oversight from a senior librarian. Search terms from 
other reviews will be scrutinized and should additional relevant search terminology arise, a 
justification for inclusion will be made and an audit trail will be maintained. MeSH terms 
will be sought. In order to capture all countries in SSA, the PubMed list of Sub-Saharan 
African countries will be used. From initial scoping, qualitative data on the HPV vaccine in 
SSA appears to be relatively scarce, justifying the use of a broad range of search terms to 
increase sensitivity of the search, to maintain a broad scope and to encompass all relevant 
studies and search terminology (Barnett-Page & Thomas, 2009; Bramer et al., 2017; Harris et 
al., 2018). The table below includes initial MeSH terminology and key words that will be 
used in the search, as well as the PubMed filter for Sub-Saharan African countries. Since this 
is a qualitative analysis, the search strategy will be iterative in nature, and a thorough audit 
trail will be maintained for transparency and replicability.  
  
Table 1: Search terms  
Population ("Papillomavirus Vaccines"[Mesh] OR "Human 
Papillomavirus Recombinant Vaccine 
Quadrivalent, Types 6, 11, 16, 18"[Mesh] 
OR 
“human papillomavirus vaccine” OR “HPV 
vaccine” OR “human papillomavirus vaccination” 
OR “HPV vaccination”) 
 
Interest AND 
"Health Knowledge, Attitudes, Practice"[Mesh]  
OR 
Knowledge OR attitude OR attitudes OR belief OR 
beliefs OR perceptions OR perception  
OR comprehend OR comprehension OR experience 
OR experiences OR understand OR understandings 
OR feel OR feelings OR opinion OR opinions OR 
point of view OR view OR views  
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Context AND 
("Africa"[Mesh] OR "Africa South of the 
Sahara"[Mesh] OR "Africa, Central"[Mesh] OR 
"Cameroon"[Mesh] OR "Central African 
Republic"[Mesh] OR "Chad"[Mesh] OR 
"Congo"[Mesh] OR "Democratic Republic of the 
Congo"[Mesh] OR "Equatorial Guinea"[Mesh] OR 
"Gabon"[Mesh] OR "Sao Tome and 
Principe"[Mesh] OR "Africa, Eastern"[Mesh] OR 
"Burundi"[Mesh] OR "Djibouti"[Mesh] OR 
"Eritrea"[Mesh] OR "Ethiopia"[Mesh] OR 
"Kenya"[Mesh] OR "Rwanda"[Mesh] OR 
"Somalia"[Mesh] OR "South Sudan"[Mesh] OR 
"Sudan"[Mesh] OR "Tanzania"[Mesh] OR 
"Uganda"[Mesh] OR "Africa, Southern"[Mesh] OR 
"Angola"[Mesh] OR "Botswana"[Mesh] OR 
"Lesotho"[Mesh] OR "Malawi"[Mesh] OR 
"Mozambique"[Mesh] OR "Namibia"[Mesh] OR 
"South Africa"[Mesh] OR "Swaziland"[Mesh] OR 
"Zambia"[Mesh] OR "Zimbabwe"[Mesh] OR 
"Africa, Western"[Mesh] OR "Benin"[Mesh] OR 
"Burkina Faso"[Mesh] OR "Cabo Verde"[Mesh] 
OR "Cote d'Ivoire"[Mesh] OR "Gambia"[Mesh] 
OR "Ghana"[Mesh] OR "Guinea"[Mesh] OR 
"Guinea-Bissau"[Mesh] OR "Liberia"[Mesh] OR 
"Mali"[Mesh] OR "Mauritania"[Mesh] OR 
"Niger"[Mesh] OR "Nigeria"[Mesh] OR 
"Senegal"[Mesh] OR "Sierra Leone"[Mesh] OR 
"Togo"[Mesh]) 
OR 
"Africa" OR "Sub Saharan Africa" OR " Central 
Africa " OR "Cameroon" OR "Central African 
Republic" OR "Chad" OR "Congo" OR 
"Democratic Republic of the Congo" OR 
"Equatorial Guinea"  OR "Gabon" OR "Sao Tome 
and Principe" OR " Eastern Africa " OR “East 
Africa” OR "Burundi" OR "Djibouti" OR "Eritrea" 
OR "Ethiopia" OR "Kenya" OR "Rwanda" OR 
"Somalia" OR "South Sudan" OR "Sudan" OR 
"Tanzania" OR "Uganda" OR " Southern Africa" 
OR "Angola" OR "Botswana" OR "Lesotho" OR 
"Malawi" OR "Mozambique" OR "Namibia" OR 
"South Africa" OR "Swaziland" OR "Zambia" OR 
"Zimbabwe" OR " Western Africa" OR “West 
Africa” OR "Benin" OR "Burkina Faso" OR "Cabo 
Verde" OR "Cote d'Ivoire" OR "Gambia" OR 
"Ghana" OR "Guinea" OR "Guinea-Bissau" OR 
"Liberia" OR "Mali" OR "Mauritania" OR "Niger" 
OR "Nigeria" OR "Senegal" OR "Sierra Leone" 
OR "Togo" 
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Article inclusion and exclusion criteria  
 
In order for articles to be considered relevant for this review, the following inclusion criteria 
must be met:   
i.) Included article publication dates must range between 2006 to the date of 
search. This date range is intended to capture stakeholder experiences, 
understandings and perspectives of the HPV vaccine since the introduction of the 
HPV vaccine in 2006. 
ii.) Included articles must take place in a country in SSA.    
iii.) Included articles must be methodologically qualitative in both data collection 
and data analysis. The search strategy will not be limited to qualitative study 
designs alone in order to identify and utilize qualitative components of mixed 
methods studies, as to which such components must also be methodologically 
qualitative in nature (both for data collection and analysis procedures).  
iv.) Articles must examine one or more relevant themes that contribute to how 
stakeholders understand the HPV vaccine in SSA. Such themes could include 
HPV vaccine experiences, perceptions, knowledge, beliefs, attitudes etc.  
v.) Articles must be published in English. Although this introduces bias, this 
review will acknowledge such limitations. 
vi.) Articles must include perspectives from stakeholders who contribute to the 
‘demand’ for the HPV vaccine including adolescents, caregivers, teachers, 
health care providers, and political, community and religious leaders etc. Any 
other relevant demand-side stakeholders that the literature may bring forth will be 
documented through an audit trial and will be justified for inclusion based on the 
aims of the review.  
 
Articles examining HPV-related health outcomes (such as cervical cancer) that do not include 
relevant data on the HPV vaccine and HPV vaccination in SSA will not be included. For the 
purpose of this review, articles must have qualitative data specifically relating to HPV 
vaccine or HPV vaccination services in SSA. Studies on vaccination in general, but do not 
explicitly include the HPV vaccine will also be excluded.  
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Article selection 
 
Due to the nature of the mini dissertation stipulations, there will be one lead reviewer (CD) 
with input from two overseeing supervisors (AS & SC). After the search strategy has been 
run in the named databases, the results will be assessed for titles and abstract eligibility. 
Relevant articles will be uploaded into Endnote where duplicates will be identified and 
removed. Following this, full text review of eligible studies will assess adherence to inclusion 
criteria. The two over seeing supervisors (AS & SC) will randomly identify 20% of 
title/abstracts and 20% of full text articles and will individually review them (10% per 
supervisor) against the inclusion and exclusion criteria as a method of increasing rigour. Any 
disagreements on article selection will be resolved via discussion between CD and one or 
both of the supervisors (AS & SC). A list of eligible studies will then be collated and basic 
background information will be maintained in a study log including first author, year of 
study, study location, study population, data collection and analysis methods and authors 
aims (Appendix C). Based on the Cochrane Qualitative Research Methods Group for 
searching qualitative evidence (Harris et al., 2018), a search strategy will be developed and 
adapted for each database (Appendix A). A PRISMA flow diagram will be created to show 
search results and the process of screening and selecting studies for inclusion.  
 
Data extraction  
 
Once studies are coded and initial themes are solidified, the data extraction table will group 
collated data by potential themes and will maintain the source of data (original transcripts, 
participant quotes from analysis or secondary author interpretations). The form will be used 
to extract primary themes or first-order constructs (original participant quotes) and secondary 
themes or second-order constructs (author’s analysis or interpretations) from individual 
studies (Appendix C). 
 
Appraisal of evidence 
 
Included qualitative studies (methodological and analytical) and the qualitative components 
of mixed methods studies will be critically appraised using the Critical Appraisal Skills 
Programme (CASP) checklist (Appendix E). Through the use of the CASP quality 
assessment tool, this review will systematically assess each article’s validity and applicability 
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of results which will ultimately provide a level of confidence in the relevance, richness and 
depth of the qualitative data that the study contributes to answering the review question 
(CASP, 2018 ). Studies will not be excluded based off the CASP assessment alone, but will 
speak to the level of confidence in the findings of each study and therefore how much each 
study is utilized in the thematic analysis (CASP, 2018 ). 
 
Data synthesis  
 
This review will utilize a thematic analysis approach to interpret and synthesize results across 
various studies in order to contribute to the knowledge around stakeholder understandings of 
the HPV vaccine across SSA (Cahill et al., 2018; Tong et al., 2007). This review will follow 
Braun and Clarkes 6-step framework for summarizing, organizing, and analysing data into an 
interpretive thematic analysis (Braun & Clarke, 2006). Since this systematic review aims to 
answer a specific research question, semantic themes will be developed based off of the 
explicit evidence from the qualitative data (Braun & Clarke, 2006). The 6-step framework is 
outlined below:  
• Become familiar with the data  
• Generate initial codes  
• Search for themes  
• Review themes  
• Define themes  
• Write up and analyse  
(Braun & Clarke, 2006). 
A thematic analysis of the available data will be conducted in order to consider a framework 
for factors that may contribute to demand-side stakeholder understandings of the HPV 
vaccine and how such factors may influence HPV vaccination services in SSA, potentially 
producing useful insight for amending current HPV vaccination efforts, as well as shaping 
HPV vaccination campaigns in SSA in the future. 
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Timeline 
 
The initial scoping for this review began in September 2018. The data extraction process is 
will be completed by April 2019 to which a completed systematic review is expected by June 
2019.  
 
Table 1: Timeline 
 
 
 
Part A: Protocol        
First draft (all components)                                                       Due January 31, 2019 
Edits                                   Due February 10, 2019  
Final Protocol                                 Due February 15, 2019  
Part B: Literature Review        
Refined search strategy                                Due February 20, 2019 
Title and abstract screening                                                Due March 5, 2019 
Full text screening                                              Due March 10, 2019 
Literature review draft                                  Due March 15, 2019 
Edits                                                   Due April 25, 2019 
Final Literature review                                       Due April 1, 2019 
Part C: Manuscript  
Data extraction                                                                                            Due April 10, 2019 
Appraisal                                                                                                     Due April 15, 2019 
Synthesis                                                                                                     Due April 15, 2019 
Manuscript draft                                                                                          Due April 25, 2019 
Edits                                                                                                             Due May 10, 2019 
Intention to Submit                                                            Due May 20, 2019  
Final edits (Parts A, B and C)                                                                      Due May 31, 2019 
Mini-dissertation submission                                                 Due June 30, 2019  
Dissemination                                                                          
. 
 
Once the mini dissertation has been 
graded and final corrections have 
been made, the manuscript will be 
submitted to the relevant journal 
for consideration of publication. 
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Study limitations  
 
As per mini-dissertation stipulations (University of Cape Town) there can only be one lead 
author and reviewer (CD) which introduces selection bias. This proposal acknowledges the 
risk for study limitation and publication bias due to the selection of English language only 
studies, unavoidable due to language capacity and time and resource constraints. Selection 
and publication bias will be mitigated as much as possible through triangulation with two 
overseeing supervisors who are well versed in the field, the creation of a thorough audit trail, 
detailed procedures outlining the process of the thematic analysis for replicability purposes, 
and random sampling of title/abstracts and full texts for agreement between lead author and 
overseeing supervisors.    
 
Ethical Considerations 
 
This qualitative systematic review will utilize existing research on HPV vaccination in SSA 
and therefore does not need ethical review or considerations as it does not conduct primary 
research.  
 
Dissemination 
 
This mini-dissertation will be available on the University of Cape Town’s thesis library. The 
manuscript portion of the outlined mini-dissertation will adhere to a pre-selected journal and 
will be written according to that journal’s formatting requirements. The manuscript portion of 
the mini-dissertation will be submitted to that journal for review for publication and 
dissemination to the larger academic community will be contingent on journal acceptance of 
the manuscript.    
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Part B: Literature Review  
 
Introduction 
 
The Human papillomavirus (HPV) is comprised of more than 150 related viruses that derive 
from the Papillomaviridae family (WHO, 2018). The variety of HPV viruses are commonly 
known as HPV ‘types’, which are grouped into low and high risk types depending on the 
health outcomes caused (CDC, 2016a; Feller et al., 2009; Sanclemente & Gill, 2002; WHO, 
2018). There are 40 types of HPV that affect the genital tract and are transmitted sexually 
through anal, oral, and vaginal sex, as well as skin-to-skin genital contact (CDC, 2016b; 
WHO, 2018). HPV is highly transmissible, is the most common viral infection of the 
reproductive tract and the most frequent sexually transmitted disease in the world (WHO, 
2018). HPV will likely infect or repeatedly infect most sexually active men and women 
throughout the life course, likely unknowingly, as 70-90% of HPV cases are asymptomatic 
and spontaneously resolve within one to two years (WHO, 2017, 2018).  
 
A  small proportion of persistent infections with specific HPV genotypes do not naturally 
regress on their own and instead initiate productive infection that can cause a range of distinct 
clinical manifestations including “latent infection of basal cells that is insufficient for 
infection transmission, subclinical infection that is active but asymptomatic, or clinical 
infection that initiates benign, potentially malignant, or malignant lesions” depending on the 
HPV type (Feller et al., 2009; Sanclemente & Gill, 2002; WHO, 2018). The spectrum of 
health outcomes resulting from HPV infection is dependent on dual factors; the type of HPV 
infection and the stage of maturation (WHO, 2018). Low-risk types of HPV (HPV 6, 11, 40, 
42, 43, 44, 54, 61, 70, 72, 81) are associated with benign oral lesions and genital warts and 
high-risk types (predominately HPV 16, 18 and less frequently HPV types 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59, and 66) are associated in the development of malignant epithelial 
neoplasms or cancer of the cervix, anus, penis, vulva, vagina, and oropharynx (Burd, 2003; 
Feller et al., 2009; WHO, 2018). HPV type 16 and 18 account for the largest numbers of 
HPV-related cancers globally, and together are the most common types of HPV identifiable 
in cervical cancers (Olesen et al., 2014).  
 
HPV is most often a latent infection that is unintentionally passed from person-to-person 
(WHO, 2018). Since the majority of HPV cases naturally regress on their own, testing for 
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HPV is not a commonality (WHO, 2018). HPV is most often detected in women through 
abnormal Papanicolaou test which indicates precancerous or cancerous lesions in the cervix, 
that have been reliably attributed to certain types of HPV infection (WHO, 2018). Cervical 
cancer is the most common clinical consequence of persistent HPV infection, and therefore, 
is the focus of the majority of the literature around HPV (WHO, 2019). Although HPV is 
most commonly associated with female cervical cancer, it is notable that there is considerable 
non-cervical HPV-associated cancers such as anogenital cancers of the penis and anus in 
men, along with oral, head, neck, and anal cancers amongst men and women alike (Moscicki 
& Palefsky, 2011; Olesen et al., 2014). Although HPV is a gender-neutral infection, the 
duration of this literature review will focus on female HPV-infection and cervical cancer 
outcomes.  
 
Biology of Human Papillomavirus 
 
HPV types are initially designated as cutaneous (associated with the skin) or mucosal 
(associated with mucus membranes that line the surface of internal organs (Sanclemente & 
Gill, 2002). Cutaneious HPV infection causes common warts and planters warts, whereas 
mucosal HPV causes more serious outcomes such as genital warts and cancer depending on 
acquisition of a low or high risk mucosal type of HPV (Sanclemente & Gill, 2002; WHO, 
2018). HPV gains entry through micro-abrasions in the basal cells to which the virus directly 
binds to the cell surface ligans and then adapts to the natural host of skin or mucosae 
epithelial cells, infecting and exploiting the cellular machinery (Muñoz et al., 2006; 
Sanclemente & Gill, 2002). HPV infection is instigated when single or multiple viruses 
exploit the epithelial basil cells, replicate the infected cells, and produce mature virions that 
express the viral genes (Feller et al., 2009).  
 
Although HPV is a necessary cause of cervical cancer, it is usually not considered to be 
sufficient on its own, as the spectrum of health outcomes is governed by complex interactions 
between multiple factors including the specific HPV genotype causing the infection, the 
genetic components and host immune response of the infected individual, the phenotype of 
the infected epithelial cells, and the differing environments and lifestyles in which one lives 
(Feller et al., 2009; WHO, 2018). Chronic smoking, multiparity, long-term use of hormonal 
contraceptives, and human immunodeficiency virus (HIV) co-infection have been shown to 
play a significant role in cervical cancer risk (de Sanjosé et al., 2018). Immunosuppression, a 
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symptom of HIV infection, significantly increases the risk of not only developing HPV, but 
also catalysing a more aggressive type of infection (Feller et al., 2009). HIV and HPV 
acquisition have a fluid and synergistic relationship where risk of acquisition of each disease 
is positively correlated, becoming hugely problematic in endemic areas, especially Sub-
Saharan Africa (SSA) where 70% of the global burden of HIV infection is found and where 
the rates of cervical cancer are amongst the highest in the world (Mahon, 2018; Olesen et al., 
2014; WHO, 2017).  
 
Cervical Cancer  
 
Female cervical cells are highly susceptible to HPV infection (WHO, 2018). Once persistent 
infection occurs in the cervix and remains untreated, precancerous lesions then develop and 
over time, mature into cervical cancer (WHO, 2017). Initial HPV infection typically occurs in 
young women in the first decade of sexual activity (Schiffman et al., 2007). Persistent HPV 
infection is rare and only occurs in less than 10% of new infections (WHO, 2017).  Persistent 
infection establishes as a precancer within 5-10 years and progresses into invasive cancer 
over many years, sometimes even decades (Schiffman et al., 2007). Cervical cancer is a slow 
progressing disease by nature and has multi-tiered prevention strategies that make it avertable 
through primary prevention via the HPV vaccine, secondary prevention via screening and 
tertiary prevention via surgical removal (WHO, 2018, 2019).  
 
It has been established that the prevalence of cervical cancer in women is closely related to 
the corresponding risk or incidence (Clifford et al., 2005). Although cervical cancer is indeed 
preventable, it was the fourth most common cancer in all women in 2018, representing 6.6% 
of female cancers world-wide (WHO, 2018). There are significant geographical discrepancies 
of cervical cancer prevalence and incidence rates; 85% of global incident cases and 90% of 
global cervical cancer mortality occurred in low-and middle-income countries in 2018 
(WHO, 2018). 
 
Africa bears the highest burden of cervical cancer world-wide, with age-standardized 
mortality rates more than doubling the rates of any other continent (L. Bruni et al., 2019 ). 
In SSA specifically, the age-standardised incidence rates of cervical cancer are among the 
highest in the world, reflected in the map (below) by Bruni and colleagues (L. Bruni et al., 
2019 ). Of the 81,687 annual cervical cancer deaths in Africa in 2018, 76,444 occurred in 
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SSA, where cervical cancer is the second most common cancer in women (L. Bruni et al., 
2019 ). The highest incidence rates of cervical cancer in SSA are in Eastern, Middle, and 
Southern Africa with standardized mortality rates of 30, 21.1, and 20 per 100,000 women 
respectively (L. Bruni et al., 2019 ).  
 
Source: (L. Bruni et al., 2019 ) 
 
The HPV vaccine 
 
The introduction and widespread use of vaccines has curbed and eradicated the occurrence of 
several infectious diseases and has been called one of the greatest public health achievements 
in the twentieth century, as increased immunization rates have resulted in significantly 
decreased risk of the disease at the population level (Malone & Hinman, 2003). The HPV 
vaccine is no exception to this, affording direct protection against the most common cancer 
causing types of HPV, if ideally administered before the onset of sexual activity (WHO, 
2018). The HPV vaccine increases the human bodies level of immunogenicity, producing 50 
times more titres of neutralising antibodies than what would be produced by natural infection, 
which should future infection occur, pre-emptively prepares the antibodies to attach to the 
human papillomavirus and prevent it from infecting the cells of the body (NCI, 2018 ; 
Schiffman et al., 2007).  
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In 2006, Gardasil, a quadrivalent vaccine that targets HPV types 6, 11, 16, and 18, was 
released as the first prophylactic HPV vaccine approved by the United States Food and Drug 
Administration (FDA) (WHO, 2017). In 2009, a bivalent HPV vaccine, Ceravix, followed 
and was aimed at targeting the most common types of HPV (types 16 and 18) (WHO, 2017). 
In 2014, the nonavalent vaccine, Gardasil9 was then approved and targeted HPV types 6, 11, 
16, 18, 31, 33, 45, 52, and 58 (WHO, 2017). If given to individuals before the onset of sexual 
activity, all three of the HPV vaccines are nearly perfect in terms of efficacy for protecting 
against the types of HPV that are targeted (NCI, 2018 ; Schiffman et al., 2007; WHO, 2017). 
 
Although the HPV vaccines are now currently available for males and females alike, it wasn’t 
until 2014 that the US Advisory Committee on Immunisation Practices approved the initial 
routine use of the quadrivalent vaccine, Gardasil, for males (NCI, 2018 ; Olesen et al., 2014; 
WHO, 2017). The gender-based time lag of HPV vaccine approval is of notable importance 
as it inherently created significant global disparities between sexes in the prevention of HPV-
related cancers which has contributed to an unrelenting  perception that HPV is a feminized 
disease and health problem (Chido-Amajuoyi et al., 2019). Globally, the HPV vaccine and 
the “initial licensure and marketing aimed strictly at adolescent girls and not boys, [caused] 
confusion about HPV infection, the HPV vaccine and sexual activity, and outrage over early 
industry efforts to promote legislation requiring the vaccine” (Brewer et al., 2017). In turn, 
these energies have been transformed into a global unease towards the HPV vaccine among 
stakeholders, which has slowed the adoption of the HPV vaccine to this day, regardless of 
abundant data showing high effectiveness and safety of the HPV vaccine (Brewer et al., 
2017; Chido-Amajuoyi et al., 2019; WHO, 2018).  
 
The HPV vaccine in Sub-Saharan Africa 
 
Although Africa bears the highest burden of cervical cancer world-wide, as of June 2018, 
only ten African countries (including Libya), and nine Sub-Saharan African countries have 
included the HPV vaccine into National Immunisation Programmes: Botswana (2015), 
Lesotho (2012), Rwanda (2011), Sao Tome and Principe (2016), Senegal (2016), Seychelles 
(2014), South Africa (2014), Uganda (2012), and Mauritius (2016) (Black & Richmond, 
2018; L. Bruni et al., 2019 ; Chido-Amajuoyi et al., 2019; Gallagher et al., 2018). Twenty-
two Sub-Saharan African countries currently have or have previously had HPV vaccine 
demonstration projects in place: Benin, Burundi, Burkina Faso, Cameroon, Cote d′Ivoire, 
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Ethiopia, Gambia, Ghana, Kenya, Liberia, Madagascar, Malawi, Mali, Mauritania, 
Mozambique, Niger, Nigeria, Sierra Leone, Tanzania, Togo, Zambia, and Zimbabwe (L. 
Bruni et al., 2019 ; Dochez et al., 2017), largely through the support the Global Alliance for 
Vaccines and Immunizations (GAVI), an international public-private health partnership 
committed to increasing access to immunizations in developing countries, along with 
additional donors of the World Health Organization, UNICEF, and PATH (Dochez et al., 
2017).  
Rollout of the HPV vaccine in SSA has not been without its unique challenges. According to 
Dochez and colleagues, the HPV vaccine inherently produces unique public health 
considerations including the involvement of  “an older target age group (9–14 year-olds 
instead of infants and young children), preferred delivery platforms of a school-based 
programme (instead of primary health care facilities) and therefore the involvement of 
multiple authorities at country level (Ministry of Health and Ministry of Education), socio-
behavioural and gender issues as girls are being targeted, the stigma of HPV being a sexually 
transmitted infection and delayed tangible health benefits of the HPV vaccine as there is a 
long delay in demonstrating the vaccines control and impact” (Dochez et al., 2017). 
Additionally, very few African countries have strong adolescent health programs which may 
be essential for effective delivery (Dochez et al., 2017).  
 
Research has been conducted on ‘supply-side’ barriers and facilitators of HPV vaccination in 
SSA and have found that a variety of top-down factors including poor service access, 
inadequate infrastructure and sustainable financing, limited health worker training, competing 
morbidities, vaccine cost, inaccessibility to medical care, and cold chain capacity constraints, 
have played a role in slow HPV vaccine uptake, (Abdullahi et al., 2014; Black & Richmond, 
2018; Perlman et al., 2014; WHO, 2019). Health inequities, gender disparities, and 
socioeconomic and cultural factors also play significant roles in cervical cancer screening and 
early detection in Africa where cervical cancer is not typically not identified or treated until 
advanced stages (WHO, 2018, 2019). The World Health Organization predicts that at least 
one third of all HPV-related cancers in Africa could be prevented with comprehensive 
vaccination implementation (WHO, 2019).  
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Vaccination facilitators and barriers  
 
A key factor in vaccination uptake in low-and middle-income countries is whether relevant 
stakeholders actively seek a vaccine, and therefore create a vaccination ‘demand’ (Brewer et 
al., 2017). In this review, demand-side stakeholders will be considered to be adolescents, 
caregivers, health care providers, teachers, and political, religious and community leaders. 
There are multi-faceted factors that contribute to where relevant stakeholders fall on the 
spectrum of attitudes and beliefs towards the HPV vaccine. It is hypothesized that attitudes 
towards the HPV vaccine sit on a spectrum that mirrors the continuum of attitudes towards 
vaccines more generally with active HPV vaccination support and active HPV vaccination 
refusal on either end of the spectrum, and HPV vaccination hesitancy somewhere in the 
middle of the continuum (Cooper et al., 2019).   
 
To date, meta-analyses have shown that risk appraisals are the most significantly correlated 
factor to vaccination behaviour, with perceived likelihood of disease, perceived severity of 
disease, and anticipatory regret directly contributing to an individual’s behaviour towards a 
given vaccine (Brewer et al., 2017). Research has found that peoples thoughts and feelings 
inform their motivations or non-motivations to get vaccinated (Brewer et al., 2017). In a 
report that draws on hundreds of psychological and behavioural science studies of 
vaccinations, Brewer and colleagues found that “thoughts and feelings can motivate getting 
vaccinated- with risk beliefs and anticipated regret about the infectious disease established as 
reliably correlated with getting vaccinated and low confidence in vaccine effectiveness and 
concern about safety reliably correlated with not getting vaccinated” (Brewer et al., 2017). 
This sentiment is reinforced by previous experience in countries such as Cameroon and 
Uganda in regards to the tetanus toxoid campaigns and in Nigeria in regards to the oral polio 
vaccine where resistance to immunization became wide-spread when public figures 
expressed concerns about the safety of the vaccines in turn creating a rhetoric that had 
monumental influence on the public’s perceptions of the vaccines (Leach & Fairhead, 2008; 
Yahya, 2007).  
 
Sub-Saharan African literature around HPV and the HPV vaccine has assessed attitudes in a 
plethora of different ways, ultimately creating a wide range of interchangeable terminologies 
such as HPV and HPV vaccine : ‘facilitators’, ‘knowledge’, ‘awareness’, ‘acceptability’, 
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‘attitudes’, ‘beliefs’, ‘intention’, ‘efficacy’, ‘perceptions’, ‘uptake’, and ‘perspectives’ and 
inversely, antonyms such as HPV and HPV vaccine: ‘barriers’, ‘hesitancy’, ‘refusal’, 
‘scepticism’, ‘denial’, ‘concerns’ and ‘fear’ (Abdullahi et al., 2014; Melissa S. Cunningham 
et al., 2014; Lacombe-Duncan et al., 2018; Newman et al., 2018; Perlman et al., 2014; 
Radisic et al., 2017; Santhanes et al., 2018; Trim et al., 2012). Although the fore mentioned 
factors are, in theory, distinct and separate constructs, literature around HPV and the HPV 
vaccine has often used them as similar and overlapping terminologies, which has made 
theory around HPV and the HPV vaccine in SSA challenging to tease apart (Brewer et al., 
2017).   
 
The Gap in Research 
 
Research in Africa has included exploration of knowledge, attitudes and practices of general 
adolescent vaccination and findings included sub-optimal knowledge about vaccine 
preventable diseases among adolescents, parents, and teachers (Abdullahi et al., 2014). Two 
systematic reviews supported this notion about HPV and the HPV vaccine specifically, 
concluding that although there was low to moderate levels of knowledge and awareness of 
cervical cancer, HPV, and the HPV vaccine among parents, teachers, and adolescents in SSA, 
that there was a willingness and understanding of the importance of being knowledgeable on 
the HPV vaccine, though the disconnect for this was unclear (Abdullahi et al., 2014; Perlman 
et al., 2014). High levels of willingness and acceptability towards the HPV vaccine in SSA 
among parents, adolescents and teachers has been attributed to the notion that the HPV 
vaccine provides direct protection against cervical cancer acquisition (Abdullahi et al., 2014; 
Perlman et al., 2014). Contrary to Brewer and colleagues’ assumption that risk appraisals are 
the most significantly correlated factor to actual vaccine initiation, Santhanes and colleagues 
found that the perception of the risk of HPV was high in Africa (ranging from 41-78%), yet 
the relationship between risk appraisal and intention to vaccinate was mixed (Santhanes et al., 
2018). Given the incredible impact and value that vaccination has had, “its underuse in 
countries where it is available and affordable is an avoidable tragedy that is an ongoing crisis 
that has motivated further research into understanding why people get vaccinated and why 
they do not” (Brewer et al., 2017). Thus far, both quantitative and qualitative data on HPV 
vaccination coverage in Sub-Saharan African countries is limited compared to countries in 
Europe and North America (WHO, 2017). There is a lack of qualitative exploration of how 
relevant demand-side stakeholders understand the HPV vaccine in SSA. Undertaking such 
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research will not only be useful in improving current HPV vaccination rollout strategies, but 
will also contribute to future strategies where demand-side stakeholder opinions and 
understandings are not only likely to be acknowledged, but also utilized in shaping effective 
HPV vaccination programmes that can potentially curb the cervical cancer epidemic in SSA.  
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Abstract 
 
Cervical cancer rates in Sub-Saharan Africa (SSA) are amongst the highest worldwide. The 
Human Papillomavirus (HPV) vaccine provides primary protection against the most common 
cancer-causing strains of HPV, including those that cause cervical cancer. There has been an 
increase in Sub-Saharan African countries that have introduced the HPV vaccine. Research 
has been conducted on supply-side barriers and facilitators to HPV vaccine uptake in SSA. In 
order to compliment such research and to inform current and future implementation 
approaches, this qualitative systematic review explored stakeholder understandings, 
perspectives, and experiences of the HPV vaccine in SSA. Thirty-one studies were found 
eligible for inclusion and were analysed thematically using Braun and Clarke’s methods for 
conducting a thematic analysis. The quality of included studies was assessed using the 
Critical Appraisal Skills Programme (CASP) checklist. The review found that HPV vaccine 
knowledge is intertwined with misinformation, that fear shapes contradictory perceptions 
about the HPV vaccine and that social norms and gender dynamics are relevant factors in 
how stakeholders understand the HPV vaccine in SSA.  
 
Keywords: Human Papillomavirus (HPV); Human papillomavirus vaccine (HPV vaccine); 
Sub-Saharan Africa (SSA); thematic analysis; systematic review; qualitative  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
38 
Introduction 
 
Human papillomavirus (HPV) is the established causative agent of cervical cancer which is 
the most common clinical consequence of HPV infection (WHO, 2018). Cervical cancer is 
the second most common cancer among women in Africa, which as a continent, has an 
estimated population of 372.2 million women aged 15 years and older who are at risk of 
developing cervical cancer (L. Bruni et al., 2019 ). Roughly 119,284 new cases of cervical 
cancer are diagnosed annually in Africa, the vast majority of which occur in Sub-Saharan 
Africa (SSA) (L. Bruni et al., 2019 ). There is growing evidence that HPV is also a relevant 
factor in other anogenital and head and neck cancers in both men and women (L. Bruni et al., 
2019 ). There are 40 types of HPV that affect the genital tract and are transmitted sexually 
through anal, oral, and vaginal sex, as well as skin-to-skin genital contact (CDC, 2016b; 
WHO, 2017, 2017 ). HPV is highly transmissible, with estimations that two thirds of those 
who have had sexual contact with HPV-infected persons will become infected themselves 
(CDC, 2016b; WHO, 2018). HPV is the most common viral infection of the reproductive 
tract and the most common sexually transmitted disease in the world (CDC, 2016b; Feller et 
al., 2009; WHO, 2018).  
 
The HPV vaccine was first introduced in 2006 and offers primary protection against the most 
common cancer-causing strains of HPV (types 16, 18, 6, 11, 31, 33, 45, 52 and 58) (WHO, 
2017). In SSA, late presentation to care (only after symptoms present) is an established and 
common health trend (WHO, 2017, 2018). Late stages of disease detection, along with health 
inequities, gender disparities, socioeconomic and cultural factors have been key drivers in 
high rates of cervical cancer mortality in SSA (WHO, 2017 ). The World Health 
Organization (WHO) estimates that at least one third of all HPV-related cancers in Africa 
could be prevented with comprehensive vaccination implementation (WHO, 2017 ). 
 
As of June 2018, ten African countries (including Libya (2013)), and nine Sub-Saharan 
African countries have included HPV vaccination in their National Immunisation Programs: 
Botswana (2015), Lesotho (2012), Rwanda (2011), Sao Tome and Principe (2016), Senegal 
(2016), Seychelles (2014), South Africa (2014), Uganda (2012), and Mauritius (2016) (Black 
& Richmond, 2018; L. Bruni et al., 2019 ; Chido-Amajuoyi et al., 2019; Gallagher et al., 
2018). Twenty-two SSA countries have HPV vaccine demonstration projects in place: Benin, 
Burundi, Burkina Faso, Cameroon, Cote d′Ivoire, Ethiopia, Gambia, Ghana, Kenya, Liberia, 
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Madagascar, Malawi, Mali, Mauritania, Mozambique, Niger, Nigeria, Sierra Leone, 
Tanzania, Togo, Zambia, and Zimbabwe (L. Bruni et al., 2019 ; Dochez et al., 2017). Recent 
momentum around the HPV vaccine in SSA over the last 5 years is largely through the 
support of the Global Alliance for Vaccines and Immunization (GAVI), an international 
public-private health partnership committed to increasing access to immunizations in 
developing countries, along with additional donors including the World Health Organization, 
PATH and UNICEF (Dochez et al., 2017).  
 
In order for any type of vaccination to be successful, high levels of uptake are required in 
order to promote herd immunity, a notion where enough people in the population are 
vaccinated so the pathogen cannot reproduce (Brewer et al., 2018). In 2014, the estimated 
coverage of the HPV vaccine in African women age 10-20 years old was 1-2% (Bruni et al., 
2016; Chido-Amajuoyi et al., 2019). From 2013-2015, Gavi implemented roughly 20 HPV 
vaccine demonstration projects, the majority of which were in SSA, and were anticipated to 
reach a total of about 400,000 women (Bruni et al., 2016). Since implementation expansion 
in 2015, recent and accurate data on HPV vaccination coverage is limited or unavailable for 
most countries that have introduced the HPV vaccine into national immunisation programmes 
or through demonstration projects (Black & Richmond, 2018). Based on available data from 
South Africa, Seychelles, Senegal, and Rwanda, Black and Richmond estimate that National 
immunisation programmes HPV coverage rates range from 72% in South Africa to 98.7% in 
Rwanda (Black & Richmond, 2018), yet comprehensive HPV vaccination coverage rates for 
the whole of SSA remain unclear due to a lack of available health informatics post-
implementation. According to Gavi, all five of the countries with the highest numbers of 
deaths from cervical cancer remain in SSA, highlighting the major public health concern of 
the continued prevalence and incidence of cervical cancer and the need for increased uptake 
of the HPV vaccine in SSA (GAVI, 2018).  
 
Factors that contribute to coverage rates of the HPV vaccine in SSA are multifactorial 
(WHO, 2017 ). Previous research in SSA has largely focused on supply-side barriers to HPV 
vaccination which threaten the success of HPV vaccine implementation. Such research has 
found, for example, that poor health system capabilities, inaccessibility to medical care, low 
cervical cancer screening levels, inadequate infrastructure, finances, and health worker 
training are significant systemic barriers to HPV vaccination success (Bingham et al., 2009; 
Black & Richmond, 2018; Francis et al., 2011; Harries et al., 2009; Perlman et al., 2014).  
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Despite a steady rise in the number of African countries introducing the HPV vaccine into 
national immunisation programmes and demonstration/pilot projects, along with extensive 
data showing the safety and effectiveness of the HPV vaccine, there is clear controversy 
when it comes to actual HPV vaccination behavior in SSA (Brewer et al., 2018; CDC, 2016b; 
WHO, 2019). Persistent skepticism around the HPV vaccine has contributed to stakeholder 
uncertainty in vaccination behaviour and actual decision making around the HPV vaccine. 
This has motivated further research into understanding why people get vaccinated and why 
they do not, especially given “the incredible impact and value that vaccination has had” and 
the continued lack of clarity around low levels of HPV vaccination uptake in countries where 
it has become available and affordable (Brewer et al., 2017).  
 
Rather than further contribute to knowledge of the HPV vaccine from a health systems 
perspective, this review aimed to explore perspectives and understandings of relevant 
stakeholders who are decision-makers and end-users of the HPV vaccine in SSA. Such 
stakeholders would be considered individuals who are invested in creating a ‘demand’ for the 
HPV vaccine, including adolescents, parents and caregivers, teachers and health care 
providers, and political, community and religious leaders. By exploring an ‘end-user’ or 
‘demand-side’ point of view, understandings of the HPV vaccine may further highlight and 
add perspective to factors that promote or inhibit HPV vaccination efforts in SSA, that are 
identified and validated by demand-side stakeholders themselves. Much of the previous 
research has been around health-system and supply-side exploration of the HPV vaccine from 
a quantitative point of view (Bardají et al., 2018; Compaore et al., 2016; Dairo et al., 2018; 
Dreyer et al., 2015; Newman et al., 2018). In contrast, this review aims to utilize qualitative 
research to gain a variety of demand-side stakeholders and users understandings of the HPV 
vaccine in the Sub-Saharan African context, where health informatics and research around 
the HPV vaccine are scarce compared to high-income country counterparts (Du et al., 2015; 
Durham et al., 2016; Markowitz et al., 2018). Utilizing empirical qualitative evidence from a 
variety of stakeholder point of views provides the opportunity to highlight factors that 
influence HPV vaccination behaviour and decision-making processes from stakeholders who 
hold various levels of status on the spectrum of ‘demand’ for the HPV vaccine in SSA. This 
includes recipients of the HPV vaccine (such as adolescents themselves) amongst stakeholder 
perspectives, whose views are often marginalized compared to higher-level stakeholders 
(such as politicians), thus giving a comprehensive spectrum of understandings of the HPV 
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vaccine from demand-side stakeholders in SSA.  
 
Methods  
 
Overview  
 
Qualitative systematic review methods were utilized with the aim of capturing the complexity 
of stakeholder understandings and thought processes of the HPV vaccine in SSA. Qualitative 
research is well-placed for exploring complex beliefs and behaviours, and for understanding 
how different factors influence these (Braun & Clarke, 2006). This approach is thus 
appropriate for gaining insight into demand side stakeholder understandings, perceptions, and 
experiences of the HPV vaccine in SSA, a research question that cannot be answered utilizing 
quantitative methods alone. In the construction of this review, systematic methods were 
utilized for searching the qualitative research using strict inclusion and exclusion criteria, 
appraising the evidence using a critical appraisal tool, and synthesizing evidence using Braun 
and Clarke’s thematic analysis approach (Braun & Clarke, 2006; Brewer et al., 2018; Carlsen 
& Glenton, 2016).  
 
Aims and objectives of review question:  
 
This systematic review aims to provide contextual understanding of how demand-side 
stakeholders understand and perceive of the HPV vaccine in SSA. The main research 
question is therefore: “How do demand-side stakeholders in SSA understand the HPV 
vaccine?” This review aims to highlight emerging themes around the HPV vaccine in SSA 
that can potentially contribute to the pool of HPV vaccination knowledge in terms of what 
works, for whom, it what contexts, and why (Booth et al., 2013).  
 
The key objectives are:  
1. To identify, appraise and synthesize qualitative research evidence on how 
stakeholders understand, experience and perceive the HPV vaccine in SSA.   
2. To identify and generate themes of relevant factors of influence on stakeholder 
understandings of HPV. 
3. To identify hypotheses for subsequent consideration and assessment of current and 
future HPV vaccination roll out strategies in SSA.  
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Identifying, appraising and synthesising the qualitative evidence of stakeholders 
understandings, experiences, and perceptions of the HPV vaccine in SSA will compliment 
reviews on HPV vaccine effectiveness and contribute to understandings of the barriers and 
facilitators of successful implementation of HPV vaccination strategies in SSA (Odendaal et 
al., 2015).  
 
Search strategy 
 
As a minimum requirement, optimal searches for comprehensive systematic reviews should 
include searches from Embase, MEDLINE, Web of Science, and Google Scholar (Bramer et 
al., 2017). This review conducted systematic and comprehensive searches from March-April 
2019 using the following relevant databases: Embase (via Scopus), Scopus, MEDLINE (via 
PubMed), PubMed, EBSCOhost, Academic Search Premier, Africa-Wide Information, 
CINAHL, PsycARTICLES, PsycINFO, SocINDEX, Web of Science, and the Cochrane 
Controlled Register of Trials (CENTRAL). The search strategy was prepared with support 
from an experienced librarian based at the University of Cape Town and consisted of terms 
related to HPV and the HPV vaccine, terms related to comprehension and understandings, 
terms related to SSA, and terms related to qualitative research (Appendix A).   
 
Inclusion and exclusion criteria  
 
This review sought studies on stakeholder understandings of the HPV vaccine in SSA, 
therefore including studies on understandings, experiences, perceptions, attitudes, beliefs, 
knowledge, comprehensions, feelings, and opinions of the HPV vaccine in SSA. The 
population of interest included relevant stakeholders who create a ‘demand’ for the vaccine 
including adolescents, parents and caregivers of adolescents, teachers, health care providers, 
and political, religious, and community leaders.  
 
Only English articles were included in this review due to language capabilities of the lead 
author and review team. Eligible studies were published from 2006-June 2019 in order to 
capture all relevant data since the introduction of the HPV vaccine in 2006 (WHO, 2017, 
2018). Eligible studies had to use a qualitative study design and qualitative methods for both 
data collection and data analysis. Qualitative data collection methods included: focus group 
discussions (FGDs), in-depth interviews (IDIs), semi-structured interviews (SSIs), key 
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informant interviews (KIIs), and observation. Qualitative data analysis methods included: 
thematic analysis, ethnographies, meta-ethnographies, content analysis, phenomenological 
analysis, discourse analysis, narrative analysis, case-study analysis, and grounded theory. 
Mixed-methods study designs that had a qualitative component were included if the 
component utilized qualitative methods for both data collection and analysis. 
 
Studies outside of SSA were excluded. Studies examining HPV-related health outcomes 
(such as cervical cancer) that did not include relevant data on the HPV vaccine and HPV  
vaccination in SSA were excluded. Other studies that focused on vaccination more generally, 
but did not explicitly include the HPV vaccine, were also excluded. Studies that did not make 
use of qualitative methods for data collection and/or analysis were excluded. Systematic 
reviews that met inclusion criteria were excluded based on the nature of secondary rather 
than primary analysis. However, the reference lists of each systematic review were evaluated 
in order to identify additional relevant papers that may have been missed by the search 
strategy. Grey literature and non-English studies were excluded. 
 
 Study Selection  
 
Studies were selected through a 4-stage process: 
 
1.  Specified electronic databases were searched using the search strategy and results 
were collated into Endnote X9 where duplicates were removed. 
2.  Title and abstracts were then screened for eligibility. To maintain rigor, 20% of 
eligible title and abstracts were screened by two independent reviewers  (10% of total 
eligible title/abstracts per supervisor).  
3. Eligible title and abstracts where then reviewed for full text eligibility. In order to 
maintain rigor, 20% of all eligible full texts were screened by two independent 
reviewers (10% of total eligible full texts per supervisor). 
4. A final list of eligible studies was collated and uploaded into Covidence software for 
quality assessment and data extraction. The search process is outlined in the PRISMA 
diagram (figure 1 below) and the included studies were mapped in figure 2.  
 
Once eligible studies were finalized, data from each study was extracted in Microsoft Excel. 
Background information from each study was also extracted and included first author name, 
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year of study, year of publication, the country where the study took place, the study 
participants, the qualitative data collection and analysis methods, and the aim of the study 
(Carlsen & Glenton, 2016) (See Appendix D).  
 
Study quality assessment 
 
The 31 studies were assessed by the lead author (CD) using the Critical Appraisal Skills 
Programme (CASP) appraisal tool for quality assessment purposes. Each study was assessed 
against the CASP checklist criteria which included assessment of the following study 
features: aims of the research question, the qualitative methodology, the research design, the 
recruitment strategy, data collection, reflexivity, ethical issues being considered, data analysis 
and findings being of substantial value and evidence (Appendix E). Studies were not 
excluded based on the CASP appraisal tool assessment alone, but this assessment informed 
the analyses and overarching findings of the review.  
 
Data extraction and analysis  
 
According to Braun and Clarke (2006), thematic analysis is a “method for identifying, 
analysing, and reporting patterns (themes) within data” (Braun & Clarke, 2006). Braun and 
Clarke’s thematic analysis methods were used to systematically report experiences, meanings 
and the reality of participants across the dataset (Braun & Clarke, 2006). This review’s 
thematic analysis was conducted by the lead author (CD) and utilized an inductive approach, 
whereby theme creation was data driven and at the semantic (i.e. explicit) level to capture 
rich description of the entirety of the data set. The data extraction process was shared with 
and checked by advisors (AS and SC) . The ultimate objective was to develop an in-depth 
picture of stakeholders’ understandings of the HPV vaccine in the Sub-Saharan African 
context (Braun & Clarke, 2006).  
 
The thematic analysis was initiated by thoroughly engaging with the depth and breadth of 
content through repeated re-reading and initial identification of patterns of meaning across 
the dataset of eligible studies (Braun & Clarke, 2006). Following Braun and Clarke’s 
guidelines for thematic analysis, each individual study in the dataset was coded and 
systematically examined, with full and equal attention given to each data item in order to 
identify interesting aspects that could form the basis of repeated themes across the dataset 
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(Braun & Clarke, 2006). Upon re-review, initial re-occurring themes across studies were 
derived and copied into an excel sheet and collated together, maintaining the original source 
of data (original transcripts, direct quotes, and secondary authors analysis) for transparency 
and reflexivity. Initially, as many potential themes/patterns were coded as possible, while still 
maintaining record of surrounding data for contextual purposes (Braun & Clarke, 2006). 
Individual extracts of data were coded into all relevant and applicable themes in order to 
maintain proper conceptualization, and to also realize potential tensions within the coded data 
and to retain accounts which depart from the dominant analysis (Braun & Clarke, 2006).  
 
After all the data was initially coded and collated, codes were then sorted into potential 
broader-level themes and a mind-map approach was used to group the most substantial codes 
together and identify the overarching theme that was represented by lead author (CD) in 
collaboration with advisors (AS and SC) (Braun & Clarke, 2006). Codes were then shifted 
and loosely grouped into sub-themes in a way that supported and provided evidence for the 
overarching identified theme (Braun & Clarke, 2006). Internal homogeneity of data was 
assessed by re-reading through coded data extracts to see if they coherently supported the 
overarching theme. In several instances, initial sub-themes were collapsed into each other to 
form a more articulate sub-theme that better supported the overarching theme (for example, 
in theme 3: ‘gender dynamics in SSA’, the sub-theme ‘gender expectations’ was collapsed 
into sub-theme ‘gender influence on health seeking behavior’ in order to more concisely and 
better support the overarching theme).  
 
Distinctions between themes were then assessed in order to maintain external heterogeneity 
of themes, ensure codes worked in relation to the dataset, and also provide the opportunity to 
code additional data that may have been originally missed within themes (Braun & Clarke, 
2006). Finally, the overall themes and the components of each individual theme (made up of 
sub-themes) were confirmed and named. This was done by revisiting the coded collated data 
extractions and organizing the extracts in a logical way with potential accompanying 
narrative that clearly articulated why the sub-theme had emerged and how it contributes to 
the overarching theme. This, in turn, contributed to the greater narrative of stakeholder 
understandings, experiences and perceptions of the HPV vaccine in SSA (Braun & Clarke, 
2006). 
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Results  
 
After deduplication, abstract and title screening and full text screening, thirty-one eligible 
studies were used in this review. The initial database searched the following databases 
Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic 
Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, 
SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL) 
and produced 259 articles, of which 174 were then removed due to duplicate status. The 
remaining 85 articles were then screened and 18 articles were excluded based off of 
title/abstract screening. From there, 67 articles were screened for full text eligibility to which 
36 total articles were excluded for various reasons including the wrong study design, the 
wrong outcome being studied, the wrong study setting and the wrong patient population. 
Thus, 31 studies in total were eligible for the systematic review.  
 
Figure 1: PRISMA diagram of search strategy and results (Moher et al., 2009)  
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Study characteristics 
 
Figure 2: Included studies in thematic analysis mapped by country of origin (first author, year).  
 
As shown in figure 2, the majority of included studies came from Eastern and Southern 
Africa, predominately from Uganda, Kenya, and South Africa. All of the studies utilized 
focus group discussions or interviews (or both) for data collection methods. Thematic, 
comparative analysis, narrative synthesis, grounded theory and content analysis were the four 
methods of data analysis across studies. Included studies took place between 2006-2018. See 
Appendix D for more information about the studies.  
 
Themes 
 
Three major themes emerged from the analysis: 1) that knowledge about the HPV vaccine is 
intertwined with misinformation, 2) that fear creates contradictory perceptions of the HPV 
vaccine, 3) and that social norms and gender dynamics play a role in stakeholder 
understandings of the HPV vaccine in SSA.  
 
Theme 1: Knowledge intertwined with misinformation 
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This theme initially explores stakeholder knowledge around cervical cancer, HPV, and the 
HPV vaccine, followed by perceived causes and risk perceptions of cervical cancer, how 
language and symptomology play a role in understandings of HPV and cervical cancer and 
finally, how misinformation is present in stakeholder perceptions and understandings of the 
HPV vaccine.  
 
This review found that there was generally low levels of technical knowledge about cervical 
cancer, HPV and the HPV vaccine in SSA (Balogun & Omotade, 2018; Francis et al., 2011; 
Remes et al., 2012; Turiho et al., 2014; Vermandere et al., 2015; Watson-Jones et al., 2015). 
This was evident in the ways that people spoke about cervical cancer, HPV, and the HPV 
vaccine; asking questions that displayed confusion and uncertainty about the physiology of 
female reproductive tract affected by cervical cancer, confusion about the fact that HPV is the 
causative agent of cervical cancer, and a lack of awareness that a HPV vaccine exists 
(Balogun & Omotade, 2018; Francis et al., 2011; Harries et al., 2009; Katahoire et al., 2013; 
Ports et al., 2013; Remes et al., 2012; Watson-Jones et al., 2012). These points are illustrated 
in the participant quote from a focus group discussion in Uganda, “I have never heard about 
cancer of the cervix. What is the difference between the cervix and the uterus? We thought it 
was the same thing.” (Katahoire et al., 2008). Further evidence in this regard can be found in 
Table 2 below:  
 
Table 2: Confusion around cervical cancer and the HPV vaccine 
(Ports et al., 2013) 
 
"I've heard of it [cervical cancer], but I don’t 
know what it is"- FGD-Female-Malawi  
(Kisaakye et al., 2018) "I am not aware of the HPV vaccine, and I don't 
know what it protects against"-Interview-
Adolescent-Uganda 
(Remes et al., 2012) 
 
“That disease you are talking about, we are 
completely in the dark about it”-FGD-Tanzania-
Parent 
(Francis et al., 2011) “…they are so anxious to know about this HPV 
because no one knows about it, and for most of 
them, this is the first time they have heard about 
it.”-FGD-Participant-South Africa 
 
 
There were exceptions to a lack of technical knowledge about HPV and cervical cancer, 
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evident when some stakeholders, usually health care providers, clinicians, and educators, 
were well aware that HPV causes cervical cancer (Balogun & Omotade, 2018; Crann et al., 
2016; Francis et al., 2013). Some stakeholders were also aware that HPV infection is a silent 
infection that affects men and women alike (Francis et al., 2011). Although this was not the 
norm across all studies, where minimal technical knowledge about cervical cancer, HPV, and 
the HPV vaccine was more prominent, it does highlight the varying degrees of knowledge of 
cervical cancer, HPV, and the HPV vaccine across SSA. It is notable that even with low-
levels of baseline technical knowledge about cervical cancer, HPV, and the HPV vaccine, 
there was high levels of willingness to learn more about the HPV vaccine across several 
studies (Abdullahi et al., 2014; Francis et al., 2011; Katahoire et al., 2013; Moodley et al., 
2009; Watson-Jones et al., 2015). This is best illustrated in the statement from a participant in 
a focus group discussion in Uganda: "People say that cancer has no cure but the health 
worker told us that this cancer, which they were vaccinating against, could be prevented, so I 
was very happy because it meant that if I got vaccinated I would not die of cancer" 
(Katahoire et al., 2013).       
 
Perceived causes of cervical cancer  
 
Contradictions arose where several stakeholders expressed that they were unaware of HPV, 
how it spreads, and its consequences, yet the same stakeholders often insinuated that 
promiscuity and poor hygiene were the cause of cervical cancer (Balogun & Omotade, 2018; 
Nyambe et al., 2018; Ports et al., 2013; Vermandere et al., 2015). These stakeholders often 
implicitly had some level of awareness that HPV is sexually transmitted, evident in the quote 
from a religious leader in a focus group discussion in Nigeria: “If a woman has sex anyhow 
with different men, it can cause cancer... If you sleep with 5 men that is 5 different diseases, 8 
men means 8 different diseases…. So, if a woman sleeps around she can have cervical 
cancer" (Balogun & Omotade, 2018). Promiscuity as the cause of cervical cancer was 
supported by a father in the same focus group, quoted saying: "When a woman is 
promiscuous...there is no way she will not have the cancer, so that is what I think can cause 
the cervical cancer" (Balogun & Omotade, 2018). Others attributed sexual activity to the 
accumulation of sexually transmitted infections, that when left untreated, cause a block in a 
woman’s reproductive tract and that produces cancer from a ‘combination of several 
diseases’ (Vermandere et al., 2015).  
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Some stakeholders had difficulty with the rationale of promiscuity as the etiology of cervical 
cancer, as they themselves currently knew or had known someone with cervical cancer who 
had led a conservative lifestyle (Balogun & Omotade, 2018; Vermandere et al., 2015). There 
was cognitive dissonance around the fact that even among stakeholder acquaintances with 
cervical cancer, their partners with often healthy and seemed unaffected by HPV. This led to 
some skepticism around HPV being the true cause of cervical cancer and further displayed a 
lack of knowledge about HPV and the possibility of being an asymptomatic carrier of the 
disease (Balogun & Omotade, 2018; Vermandere et al., 2015).  
 
Other perceived causes attributed to cervical cancer across the study settings were a modern 
lifestyle of processed food and reliance on medication (Balogun & Omotade, 2018; Katahoire 
et al., 2008; Vermandere et al., 2015), genetics (Balogun & Omotade, 2018; Masika et al., 
2015; Vermandere et al., 2015), witchcraft (Nyambe et al., 2018), vaginal insertion of drugs 
(Nyambe et al., 2018; Remes et al., 2012), males as carriers (Turiho et al., 2014), existing 
STDs progressing to cervical cancer (Vermandere et al., 2015), poor sexual habits (Nyambe 
et al., 2018) and frequent childbirth or frequent abortion (Remes et al., 2012). Although 
several studies used focus group discussions and interviews to assess preliminary perceptions 
of cervical cancer, HPV, and the HPV vaccine, there was often an educational component at 
the completion of the study to address misinformation (Francis et al., 2011; Remes et al., 
2012).  
 
Risk perception of HPV and cervical cancer  
 
In general, cancer was widely feared by participants across studies (Balogun & Omotade, 
2018; Francis et al., 2011; Remes et al., 2012; Turiho et al., 2017). One opinion leader in 
Kenya explained that cancer diagnosis in Africa is comparable to the stigma and isolation of 
HIV/AIDs (Friedman et al., 2014). These connotations were also associated with cervical 
cancer, which stakeholders across studies described as ‘painful’, ‘dangerous’, ‘horrible’, 
‘incurable’, ‘deadly’, and a ‘death sentence’ (Hasahya et al., 2016; Katahoire et al., 2013; 
Ports et al., 2013). Such perceptions about cervical cancer were consistent across studies and 
were often based on stakeholder experience from knowing someone with cervical cancer and 
having watched them suffer from the disease (Balogun & Omotade, 2018; Francis et al., 
2011; Hasahya et al., 2016; Katahoire et al., 2013; Ports et al., 2013; Vermandere et al., 
2015).  
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Across the majority of all studies, it was clear that female stakeholders perceived a high risk 
of cervical cancer for both themselves and their female counterparts (Hasahya et al., 2016; 
Katahoire et al., 2008; Nelson et al., 2010; Ports et al., 2013). Often, the perceived risk of 
cervical cancer was reinforced by high rates of cervical cancer mortality from the Sub-
Saharan African country in which the stakeholder lived. The high perceived risk of a feared 
disease (cervical cancer) sparked the desire to prevent it from occurring, with this review 
finding that the perception of the HPV vaccine as a means of protection against cervical 
cancer was a key influence on stakeholders understandings of and willingness to learn about 
the HPV vaccine (Katahoire et al., 2013; Turiho et al., 2017).  
 
The fear of cervical cancer, the pain associated with it, and the desire to avoid it were 
frequently mentioned across studies, which often led stakeholders to conduct a risk 
assessment of short term pain (of the HPV vaccine injection) weighed up with long term pain 
(of potential cervical cancer diagnosis), normally reaching the conclusion that “prevention is 
better than cure” when discussing the HPV vaccine across studies (Balogun & Omotade, 
2018; Francis et al., 2011; Harries et al., 2009; Katahoire et al., 2013; Ports et al., 2013; 
Remes et al., 2012). This is further evident in two quotes from female stakeholders who 
participated in a focus group discussion in Uganda; “I have had injections before and I know 
the pain lasts a short time but I feared that the pain from cancer can last forever" and "I 
normally fear injections but when I thought about the pain that I could suffer if I got cancer I 
decided to be vaccinated no matter what" (Turiho et al., 2017).  
 
Language and symptomology 
 
How people speak about a health topic is often a good indication of what they understand 
about it (Graham & Brookey, 2008). Stakeholders spoke about cervical cancer in varying 
ways across SSA. This review supports Katahoires & colleagues’ findings that stakeholders 
do not often make distinctions between the cervix, uterus, and womb when discussing 
cervical cancer and that there are local language nuances that are vital to understanding how 
people themselves understand both disease and prevention of disease (Katahoire et al., 2008).  
 
Cervical cancer was most often referred to as ‘cancer of the womb’ in South Africa, Kenya, 
and Uganda (Francis et al., 2011; Friedman et al., 2014; Harries et al., 2009; Katahoire et al., 
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2008; Nelson et al., 2010; Vermandere et al., 2015). The HPV vaccine was referred to as the 
‘cancer of the womb vaccination’ in South Africa (Francis et al., 2011). Across studies, 
‘cancer of the uterus’ was the second most common reference to cervical cancer, supporting 
the previous finding that there was explicit confusion about the difference between the cervix 
and the uterus across some studies (Bingham et al., 2009; Katahoire et al., 2008; Katahoire et 
al., 2013; Venturas & Umeh, 2017; Vermandere et al., 2015) 
 
Cervical cancer was most commonly spoken about through explanation of its symptoms 
rather than its technical name, and the reliance on symptomology rather than terminology 
was evident across stakeholder interviews and focus groups when expressing understandings 
and perceptions of cervical cancer as a health topic (Francis & Katz, 2013; Friedman et al., 
2014; Katahoire et al., 2008; Nelson et al., 2010; Nyambe et al., 2018; Remes et al., 2012). 
When stakeholders were asked what they knew about cervical cancer, responses consistently 
included explanation or recognition of the disease through perceived symptoms (accurate or 
inaccurate), usually including vaginal bleeding, foul odor, vaginal discharge, and pain during 
intercourse (Crann et al., 2016; Hasahya et al., 2016; Nyambe et al., 2018; Remes et al., 
2012). Stakeholder reliance on symptomology is notable in understandings of HPV and 
cervical cancer in the Sub-Saharan African context.  
 
There was obvious reliance on symptomology for disease recognition, but notably, 
symptomology was also a driver in health seeking behavior (Crann et al., 2016; Hasahya et 
al., 2016; Nyambe et al., 2018). Most stakeholders expressed that symptoms of disease were 
the driver of seeking care and that getting a vaccine for something when symptoms are not 
present may inhibit action towards HPV vaccine uptake, best illustrated by a policy maker in 
Zambia expressing: “Health seeking behavior in Zambia is not the best… [A woman] will not 
go to the clinic unless she is sick…So expecting healthy people to voluntarily come for 
vaccination is difficult” (Nyambe et al., 2018). Interpreting symptomology as necessary for 
vaccination was also evident in one participant from a focus group in Kenya asking: “What 
are you vaccinating us against, yet we are not sick?” (Watson-Jones et al., 2012). Developing 
symptoms as a tangible indicator of having a disease and only then seeking care is of 
noteworthy importance as late presentation to care in advanced stages of disease is extremely 
common and has driven extreme rates of cervical cancer mortality in SSA (Crann et al., 2016; 
Hasahya et al., 2016; Nyambe et al., 2018; Ports et al., 2013). As further explored in the 
following theme, fear is a large part of late presentation and is especially relevant when 
  
53 
exploring understandings of the HPV vaccine in SSA.  
 
Misinformation  
 
Across studies, the most powerful and prevalent piece of misinformation revealed by 
stakeholders was a two-sided and polarized argument around infertility; some stakeholders 
believed (and feared) that cervical cancer itself causes infertility, while other stakeholders 
believed (and feared) that the HPV vaccine causes infertility. Misinformation was prevalent 
on both sides of the argument and it was clear that across studies, stakeholder knowledge 
about cervical cancer, HPV, and the HPV vaccine was intertwined with misinformation. 
Misinformation was perpetuated in communities in different ways; Nyambe and colleagues 
attributed persistent misinformation in Zambia to low levels of social mobilization around the 
HPV vaccine, where Masika and colleagues attributed misinformation around the HPV 
vaccine in Kenya to a lack of uniform and top-down training of relevant stakeholders ranging 
from policy makers, to health care providers, to teachers assisting with administering the 
HPV vaccine (Masika et al., 2015; Nyambe et al., 2018). Insufficient comprehensive training 
on the HPV vaccine further contributed to the gaps in rollout procedures and was considered 
to substantially damage school-based HPV vaccination programmes success in Zambia, 
Kenya, Mozambique, and Zimbabwe, where teachers (assisting health care providers 
administer the HPV vaccine to adolescent girls) expressed how they did not receive sufficient 
information on the HPV vaccine (Crann et al., 2016; Masika et al., 2015; Nyambe et al., 
2018; Soi et al., 2018; Venturas & Umeh, 2017). This is illustrated in the quotes of a teacher 
in Kenya saying, “They [the health care providers] met just some of the teachers… because 
us, we didn’t hear” (Vermandere et al., 2015), with another teacher from a different study in 
Kenya suggesting “all teachers should be given the same information…For instance, in our 
district, only the headteacher and two other teachers were called” (Masika et al., 2015).  
 
Studies also pointed to the ways that improper training around the HPV vaccine led to poor 
communication, which in turn, perpetuated existing misconceptions about the HPV vaccine, 
while inevitably also introducing skepticism, fear and uncertainty around the HPV vaccine 
within communities and even in the minds of key stakeholders such as health care providers 
and teachers (Venturas & Umeh, 2017; Vermandere et al., 2015). A prominent sentiment 
echoed in several studies was that a lack of comprehensive information given to communities 
at the onset of introduction of the HPV vaccine, almost always initiated and even expedited, 
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the spread of rumors and misinformation in its place (Friedman et al., 2014; Hasahya et al., 
2016; Masika et al., 2015; Remes et al., 2012). Such misinformation included distortion of 
technical facts such as appropriate dose schedule (Islam et al., 2018; Katahoire et al., 2013; 
Kisaakye et al., 2018), rationale for age of HPV vaccination initiation (Remes et al., 2012; 
Soi et al., 2018) and preparedness of vaccinators (Harries et al., 2009; Venturas & Umeh, 
2017). Although inaccurate, some pieces of technical misinformation were both a facilitator 
and deterrent for the HPV vaccine (evidence in Table 3 below). The following theme 
examines how misinformation is also a result of fear and contradictory stakeholder 
understandings.  
 
Table 3: Misinformation as a facilitator and deterrent to the HPV vaccine 
Misinformation as a facilitator to the HPV vaccine 
(Turiho et al., 2017)  “Since HPV and HIV are both viruses, some 
people believed that HPV vaccination can also 
prevent HIV” -FGD-Parent-Uganda  
 
 
(Turiho et al., 2017) “Some girls think that HPV vaccination can 
protect them from getting pregnant and that is 
why they go around having sex with men… The 
girls say that since they received the HPV 
vaccine, they cannot get pregnant when they sleep 
with men”- FGD-Adolescent girl-Uganda 
 
 
Misinformation as a deterrent to the HPV vaccine 
(Balogun & Omotade, 2018)    "I can't get vaccinated because most times when  
       you get too much of anything it will have  
       something… it will damage in your body" FGD- 
       Adolescent girl-Nigeria  
 
(Turiho et al., 2017) “They said HPV vaccination would in future 
cause disease to those who receive it… that, the 
injection contains chemicals that kill a person 
gradually…”-FGD-Parent-Uganda  
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Theme 2: Fear shaping contradictory perceptions of the HPV vaccine 
 
When discussing both cervical cancer diagnosis and making decisions around the HPV 
vaccine, stakeholders mentioned fear as a predominate emotion (Balogun & Omotade, 2018; 
Francis et al., 2011; Remes et al., 2012; Turiho et al., 2017). The fear of cervical cancer itself 
was so great that some females expressed that they were reluctant to seek care and would 
prefer not to know their status or diagnosis, often due to the common perception that cervical 
cancer leads to an inevitable death (Francis & Katz, 2013; Hasahya et al., 2016). This is 
evident in the quote by a female stakeholder in a focus group discussion in Uganda saying: "I 
fear going for a check-up since after getting the diagnosis of cervical cancer, I will then know 
that I am dying” (Hasahya et al., 2016). This was also supported in South Africa where 
women expressed that they do not “want to face” the possibility of cervical cancer diagnosis 
(Francis & Katz, 2013).  
 
Fear of death, suffering, pain, or reduced quality of life, and most commonly, fear of 
infertility, were mentioned as contributing to hesitance that stakeholders had when it came to 
discussing both cervical cancer and the decision (or indecision) to get the HPV vaccine, 
ironically, the very thing that protects against the cervical cancer diagnosis (Balogun & 
Omotade, 2018; Francis et al., 2011; Remes et al., 2012; Turiho et al., 2017). Fear of 
infertility as a result of cervical cancer and fear of infertility as a result of the HPV vaccine 
created a polarized debate, with stakeholders often firmly believing in one or the other as the 
etiology of infertility. This debate was emotionally fueled as male and female stakeholders 
alike placed significant value on a woman’s ability to bear children, therefore making 
infertility widely feared, highly stigmatized, shameful, and indicative of a female’s worth 
(Friedman et al., 2014; Greenfield et al., 2015; Hasahya et al., 2016; Masika et al., 2015; 
Remes et al., 2012) 
 
Although stakeholders feared cervical cancer due to perceived physical pain and suffering 
that it causes, a much more prevalent fear was the emotionally charged notion that cervical 
cancer causes infertility amongst women (Francis & Katz, 2013; Harries et al., 2009; 
Katahoire et al., 2013; Turiho et al., 2017). Depending on the timing of presentation, type of 
HPV strain, severity of symptoms, and progression of disease, infertility as a result of 
cervical cancer is indeed a possibility, but is not always a given (WHO, 2017, 2018). 
Amongst stakeholders who harbored the belief that cervical cancer diagnosis caused 
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infertility, infertility was perceived as inevitable and was by far the most detrimental 
perceived outcome of cervical cancer (Friedman et al., 2014; Hasahya et al., 2016; Katahoire 
et al., 2013; Nyambe et al., 2018; Remes et al., 2012; Soi et al., 2018; Venturas & Umeh, 
2017; Watson-Jones et al., 2015). Stakeholders who firmly believed cervical cancer diagnosis 
inherently produced infertility, clearly supported the HPV vaccine, largely to protect women 
from cervical cancer and in turn, their future fertility, illustrated from stakeholder statements 
in table 4 below: 
 
Table 4: Fears that cervical cancer would cause infertility  
Study  Quote  
(Katahoire 
et al., 2013) 
"I know that if a woman gets that cancer she cannot bear children and that is very sad"- 
FGD-Participant-Uganda 
(Francis et 
al., 2013) 
“Cervical cancer is where cells in your womb grow out of control and they need 
treatment…Uncontrollable growth of bad cells in your womb.”-FGD-Participant-South 
Africa  
 
(Katahoire 
et al., 2013) 
“I was fully vaccinated because I want to have children without any problems.”- FGD-
Adolescent girl- Uganda  
 
(Katahoire 
et al., 2013) 
“The cancer destroys your uterus and you can never have children. I do not want to die 
childless so I had to make sure that I got all three doses.”- FGD-Adolescent girl-Uganda 
(Turiho et 
al., 2017) 
“I was well taught by my teachers and the health workers who came to our school that 
the HPV vaccination would protect me from cervical cancer, which can lead to failure to 
produce children… With HPV vaccination, we shall have healthy lives in future and be 
able to give birth to children…”-FGD-Adolescent girl-Uganda 
(Turiho et 
al., 2017) 
“We would let our daughters to get vaccinated because we want them to be healthy in 
future… and have children….” -FGD-Parent-Uganda 
(Harries et 
al., 2009) 
“If it [HPV vaccine] can improve the future for all our daughters then it is a good thing. 
In the past we never knew about things like this and a lot of women’s reproductive 
organs were removed because they contracted cancer. So I think it is a good thing”- 
FGD-Participant- South Africa 
 
Ironically, other stakeholders on the opposite side of the debate expressed contrary beliefs 
that the HPV vaccine, which provides primary protection against the most common cancer-
causing strains of HPV, was in and of itself, the cause of infertility amongst women 
(Friedman et al., 2014; Katahoire et al., 2013; Remes et al., 2012; Venturas & Umeh, 2017; 
Watson-Jones et al., 2012). The origin of this sentiment could not be identified, but had a 
significant influence on some stakeholders’ perceptions of the HPV vaccine across the 
studies. The fear that the vaccine inevitably would cause infertility was the most prevalent 
reason for stakeholder hesitancy around the HPV vaccine, as evident below in table 5 of 
stakeholder statements: 
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Table 5: Fears that the HPV vaccine would inevitably cause infertility  
Study Quote  
(Katahoire et 
al., 2013) 
"I heard women in the village saying that girls that were vaccinated may not have 
babies in the future. At the time I had already received the first dose so I decided 
not to receive the other two”-FGD-Female participant-Uganda 
(Katahoire et 
al., 2013) 
"At first I agreed to be vaccinated but when I heard that the vaccinations could 
prevent me from having children I decided not to receive the other doses."-FGD- 
Female participant-Uganda  
 
(Remes et al., 
2012) 
“The vaccine could disorder and destroy the eggs that a girl has, and reproducing 
would be a problem.”- FGD-Male teacher-Tanzania 
(Turiho et al., 
2017) 
"I know some girls who did not get vaccinated because they thought that the 
vaccine against HPV would prevent them from producing children or getting 
pregnant in future… They said it destroys a woman’s egg (ovaries) so that she does 
not produce children" -FGD-Adolescent participant-Uganda 
(Hasahya et al., 
2016) 
 
"Girls vaccinated during their reproductive age will only get two children" FGD-
Participant-Uganda  
(Soi et al., 
2018) 
"There was a misbelief that we were vaccinating girls to make them sterile, to not 
be able to have children. It even reached a point when the girls were no longer 
going to school" -Interview-District Health Directorate-Mozambique 
(Katahoire et 
al., 2013) 
"I could not lie about my age to the teacher because she already knew that I was 
10, so when they sent us out to be vaccinated I quickly went towards the toilets and 
hid. I thought that perhaps they wanted to kill us or prevent us from having 
children" -FGD-Participant- Uganda  
 
(Turiho et al., 
2017) 
“Some girls think that HPV vaccination can protect them from getting pregnant and 
that is why they go around having sex with men…The girls say that since they 
received the HPV vaccine, they cannot get pregnant when they sleep with men”-
FGD- Female adolescent- Uganda 
(Turiho et al., 
2017) 
"They said it kills a woman’s eggs and she does not produce children… Some 
people got scared after being told in the villages that people who get vaccinated 
against HPV will not produce children in future… Some believed that the vaccine 
was meant to reduce fertility of women in future by destroying their ovaries…” 
-FGD-Parent-Uganda 
(Venturas & 
Umeh, 2017) 
‘‘What I have heard about the vaccine, some say that it has been developed to 
reduce the population, to reduce the fertility in a woman, an African woman.” 
FGD-Participant-Zambia 
(Venturas & 
Umeh, 2017) 
“They were saying if they give those vaccines to young girls, maybe those young 
girls they won’t get pregnant in the future, it will prevent them from getting 
pregnant, so those are beliefs that they have”-FGD-Participant-Zambia  
(Watson-Jones 
et al., 2012) 
“...the boys will enquire why it is only the girls who are getting the vaccine. . .The 
boys will discourage the girls, telling them that the vaccine will damage their 
lives.” -FGD-Community Leader, Kenya  
(Remes et al., 
2012) 
“Vaccinations in this country that are linked to issues of reproduction have had 
very bad results later on” -FGD-male teacher- Tanzania 
 
Therefore, this two-sided infertility argument was polarized, with some stakeholders 
believing that cervical cancer itself causes infertility and other stakeholders believing that 
HPV vaccine causes infertility. Both beliefs had great authority in stakeholder decisions 
around the HPV vaccine in SSA (Vermandere, 2016).  
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As evident from some of the stakeholder excepts above, the debate around the cause of 
infertility was further polarized and fueled by pertinent distrust of both local health systems 
and governments, as well as international vaccine initiatives and high-income countries who 
were perceived to be providing HPV vaccines (Bingham et al., 2009; Friedman et al., 2014; 
Venturas & Umeh, 2017; Watson-Jones et al., 2012). Stakeholders in Zambia expressed that 
the lack of information given at implementation about the HPV programme implied that a 
lack of research had been done on the HPV vaccine, and other stakeholders took this 
sentiment one step further in saying that the government must be conducting research by 
using young girls as the guinea pigs for experimentation (Bingham et al., 2009). Other 
stakeholders expressed their concerns that the HPV vaccine was a government supported 
initiative for population control methods of Africans or that Africa was receiving ‘second-
tier’ left over vaccines from first world countries (Friedman et al., 2014; Harries et al., 2009; 
Nyambe et al., 2018). These findings support previous research that have found there are 
wide-spread anti-fertility rumours and underlying suspicion of public health initiatives that 
play a role in vaccine uptake, especially the HPV vaccine (Remes et al., 2012). This 
highlights how widespread the double-sided argument around fertility and the HPV vaccine 
is - with some stakeholders seeing the HPV vaccine as a way to protect fertility, while others 
see the HPV vaccine as a danger to fertility. The lack of clarity around the issue is 
summarized in the following quote by an adolescent stakeholder from a focus group 
discussion in Uganda saying: “People say that the HPV vaccine may make us fail to bear 
children in future; but we have also been told that it is not true that the injection can cause 
infertility. So we do not know the truth” (Turiho et al., 2017). 
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Theme 3: Social norms and gender dynamics influence on understandings of the HPV 
vaccine in SSA  
 
  
When examining external influences on stakeholder understandings and interpretations of the 
HPV vaccine in SSA, there was evidence across studies that layers of social influence play a 
role in how stakeholders perceive the HPV vaccine. This is in agreement with Tuhiro and 
colleagues who found HPV vaccination behaviours, actions and attitudes are shaped by both 
exposure to information and interaction with fellow community members (Turiho et al., 
Religious 
influence
• “The Maasai have started 
understanding the 
importance [of vaccines]. 
. . .. we have seen they 
have really helped a lot, 
because ....many children 
used to be born with polio 
but nowadays it is 
difficult to find children 
with polio.”-FGD-
Religious Leader-Kenya 
(Watson-Jones, 2015)
Political 
influence
• “The former first lady 
[used to be] on television 
all the time talking about 
cervical cancer and we 
had an overwhelming 
response. The [patients] 
who were coming told us 
that [they] heard about it 
from the first lady.”-FGD-
Participant-South Africa 
(Nyambe, 2018)
Community 
leader
• “If it is done by the school 
or church, you run the risk 
of getting only the people 
involved in that school or 
church. If you do it at the 
chief’s camp, you know 
it’s for the whole 
community” -Interview-
Religious Leader-Kenya 
(Watson-Jones, 2015)
Generational 
influence 
• “Start with the village 
elders. These are the ones 
who have the loudest 
voice in the village”-
FGD-Community leader-
Kenya (Watson-Jones, 
2015).
HCP/ 
Teacher
• ‘‘The way [healthcare] 
staff members accept it 
will also impact on the 
way the general 
population will react to 
it...if we don’t accept it 
then the community won’t 
accept it’’-Interview-
HCP-Zimbabe (Crann, 
2016)
Peer 
influence 
• “Like someone wanted to 
know, "Are others taking 
their children?", but after 
that…most of them came 
and I think it was 
because they saw that 
almost everybody else 
was doing it.”-FGD-
Nurse-Kenya 
(Vermandere, 2015)
Adolescent 
autonomy 
• "My mother didnt want 
me to go and get the 
vaccine because she 
thought that maybe it 
would give us AIDS or 
something. So then I had 
to explain to her ...and she 
understood that I wanted  
to go" -FGD-Adolescent 
girl-South Africa (Katz, 
2013). 
Individual 
perceptions 
about the HPV 
vaccine  
Gender 
dynamic 
and 
gender 
influence 
in SSA  
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2017). Stakeholders expressed that they sought information, opinions, and beliefs from 
various sources and influences in the community, including political leaders, religious 
figures, community leaders, elders, health care providers, teachers, and peers. Notably, 
adolescent autonomy was also a factor, evident in some adolescents expressing they would 
get the HPV vaccine regardless of parents and caregivers beliefs about it (Katahoire et al., 
2013; Katz et al., 2013; Remes et al., 2012). These layers of social influence seemed to exist 
within a prominent gender dynamic in the Sub-Saharan African context, outlined in figure 3 
above.  
 
Many of the countries in which the studies included in this review were based, have rolled 
out HPV vaccination programmes that mainly target female adolescents in attempts to curb 
the extreme morbidity and mortality rates of cervical cancer, the most common clinical 
consequence of HPV infection in SSA (Friedman et al., 2014). Several stakeholders across 
the studies expressed confusion over HPV being a gender neutral virus and yet adolescent 
females being the only targeted population for HPV vaccination (Crann et al., 2016; Harries 
et al., 2009; Vermandere et al., 2015; Watson-Jones et al., 2012). This confusion is evident in 
a question asked by a public health nurse in Kenya; “Why target women and not men? Why 
don’t you target the source? Why don’t you put out the fire from where it starts?” (Watson-
Jones et al., 2015). 
 
Some male stakeholders expressed disinterest in the HPV vaccine since female only 
vaccination ultimately excluded males and warped perceptions that both HPV and cervical 
cancer are feminized diseases that don’t affect men (Crann et al., 2016; Harries et al., 2009; 
Vermandere et al., 2015). The necessity of having a cervix in order to be directly affected by 
cervical cancer, coupled with a traditional cultural focus of reproductive health being a part 
of a ‘woman’s job’, reinforced feminization of HPV and caused feelings of resentment, 
confusion, and distrust from stakeholders of both sexes (Harries et al., 2009; Watson-Jones et 
al., 2012). Some stakeholders called for gender neutral vaccination in the future and in the 
interim, gender neutral education since HPV affects both sexes and current generations of 
adolescents boys and girls would one day become parents and need to educate their sons and 
daughters alike (Francis & Katz, 2013; Vermandere et al., 2015).Other stakeholders 
expressed concern that just vaccinating girls was not only discriminatory, but also confusing 
for boys, especially when trying to close the unequal gendered power dynamic (Katahoire et 
al., 2013; Watson-Jones et al., 2012).  
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In some studies, stakeholders raised that the progressively early age of sexual debut of 
adolescents of both sexes was an enabling factor to support the HPV vaccine within 
communities (Harries et al., 2009; Katz et al., 2013; Turiho et al., 2017; Watson-Jones et al., 
2012). Stakeholders from such studies explained that children in the communities are 
sexually active at the early age of 10 or 11, and thus suggested that the HPV vaccine should 
be administered earlier than adolescence in order to provide maximum protection prior to 
exposure to the HPV (Harries et al., 2009). Earlier sexual debut was attributed to adolescents 
initiating sexual experimentation earlier on (Harries et al., 2009; Katz et al., 2013; Turiho et 
al., 2017; Watson-Jones et al., 2012), early and arranged marriages (Soi et al., 2018; Watson-
Jones et al., 2012) and most concerningly, age-discordant relationships and gender-based 
violence and abuse of female children and adolescents, especially in South Africa (Francis et 
al., 2011; Katz et al., 2013; Nelson et al., 2010; Nyambe et al., 2018). The HPV vaccine was 
perceived to provide some protection in an environment where some perceived gendered 
based violence to be inevitable, especially in South Africa, illustrated by one South African 
mother saying ‘‘I feel certain about [vaccinating my child] because there is AIDS and HIV 
out there and we all are aware of it…My child can be raped, and I will feel bad about it, but I 
am at peace [knowing] that she is participating in the Kganya Motsha [HPV vaccine trial] 
and will be protected against sexually transmitted diseases’’ (Katz et al., 2013). The 
inevitability of rape in South Africa was also mentioned in an interview with a Sangoma 
(Nelson et al., 2010) and a father (Watson-Jones et al., 2012) and protecting females against 
such sexual abuse outcomes was seen as facilitator for the HPV vaccine.  
 
In this manner, the HPV vaccine was seen as a harm reduction strategy against gender-based 
sexual violence, which to some stakeholders was unescapable for females (Francis et al., 
2011; Francis & Katz, 2013; Katz et al., 2013; Nelson et al., 2010; Nyambe et al., 2018). The 
reality of rape and abuse was coupled with concern about the unintended consequences of 
pregnancy and HIV and other STD acquisition, which many stakeholders expressed would be 
the responsibility and burden of the female (and not the male perpetrator) due to the unequal 
power dynamic between men and women in SSA (Harries et al., 2009; Katz et al., 2013; 
Nelson et al., 2010; Turiho et al., 2017). Such outcomes also increased the likelihood of 
abandonment by male partners seen in the quote by a health care provider in Zambia: “Most 
of the women who come [to the cancer ward] have already been left by their husbands before 
coming here….So three quarters of the [women] who are here were once married” (Nyambe 
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et al., 2018).  
 
A notable gender dynamic was also interwoven in health seeking behaviour where 
stakeholders in some studies (Zambia, Zimbabwe, Kenya and Tanzania) expressed that males 
have the ultimate say in health decisions, including vaccination (Crann et al., 2016; Nyambe 
et al., 2018; Remes et al., 2012; Venturas & Umeh, 2017; Vermandere et al., 2015). One 
female stakeholder from a focus group in Zambia explained this further:“[that there is a] the 
cultural background that a woman should seek permission from her husband, whether she 
should take her daughter for the vaccine…so those are cultural issues that will always be 
there” (Venturas & Umeh, 2017). Some teachers in Tanzania agreed, explaining that school 
meetings were not always successful when it came to educating parents and caregivers about 
the HPV vaccine for their adolescent daughters because even if the mother was convinced to 
get the daughter the HPV vaccine, that many fathers refused and had the final say in HPV 
vaccination behaviour  (Remes et al., 2012).  
 
This notion was contradicted by studies in South Africa and Malawi where stakeholders 
agreed that the responsibility for soliciting care for children lies with women, [seen in] 
mothers and other female family members taking the lead in the healthcare decisions, and 
fathers generally being absent from the process (Francis et al., 2011; Ports et al., 2013). 
Across studies, male and female stakeholders urged men to be more included in education 
around cervical cancer and HPV vaccination, as men are carriers of HPV and can also have 
cancer outcomes (Harries et al., 2009) and also because it would minimize the stigma around 
the HPV vaccine being siloed as a female responsibility and health issue (Katahoire et al., 
2013). This is further evident in the quote by one focus group participant in Zambia saying: 
‘‘…but with education we should include the male folk because mostly we side line them, 
[but] they also play an important role” (Venturas & Umeh, 2017). 
 
Discussion  
 
Three major findings emerged from this review. Firstly, this analysis found that low levels of 
technical knowledge about cervical cancer and HPV, along with minimal awareness of the 
existence of the HPV vaccine, contribute to misinformation amongst Sub-Saharan African 
communities and countries. This supports previous reviews in Africa and SSA more 
specifically (Abdullahi et al., 2014; M. S. Cunningham et al., 2015; Francis & Katz, 2013; 
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Perlman et al., 2014). Misinformation is fueled by both rumors and fear, both of which 
simultaneously contribute to a growing suspicion and distrust of vaccination programmes (in 
general and HPV vaccination specifically) in SSA. Distrust of HPV vaccination inevitably 
feeds back into the stream of misinformation and has left many stakeholders unable to 
disentangle the persisting parallel knowledge and misinformation around the HPV vaccine 
that perseveres in SSA.  
 
Secondly, beliefs around infertility have created a significant divide in stakeholder 
understandings of the HPV vaccine in SSA. This review found that demand side stakeholders 
largely have two opposing perceptions about the causes of infertility; one side attributing 
infertility to cervical cancer diagnosis, in turn, making such stakeholders supportive of the 
HPV vaccine as it prevents the most common cancer-causing strains of HPV and the other 
side attributing infertility to the HPV vaccine itself, therefore igniting HPV vaccine hesitancy 
and out right refusal amongst stakeholders who harbor such beliefs. These divergent 
perspectives on infertility have been a major factor in stakeholder understandings of the HPV 
vaccine and will have to be addressed in order to get Sub-Saharan African countries to fully 
invest in uptake of the HPV vaccine.  
 
Thirdly, social layers of influence not only affect where stakeholders get information on the 
HPV vaccine, but also how stakeholders perceive and process the information about the HPV 
vaccine in relation to the source from which it originated. This was evident in some 
stakeholders requesting validation or further information about the HPV vaccine from certain 
stakeholders, usually of greater social status, such as the government or religious leaders 
whom many stakeholders perceived to act in the best interest of the community. However, as 
mentioned previously, there were some stakeholders who distrusted the government and were 
skeptical that the intentions of the HPV vaccination programmes were actually a covert 
population control method. The disconnect in where and whom stakeholders choose to place 
their trust is of notable importance. Within social layers of influence, a notable gender 
dynamic emerged as a significant factor in how stakeholders perceive the HPV vaccine. 
Gendered dynamics included the perception that the HPV vaccine was a viable harm 
reduction strategy against gender-based violence, that there are significant differences in 
gendered decision-making about health seeking behaviors across countries in SSA, and 
finally, that female-only vaccination warps perceptions of HPV to be a female-only issue 
which perpetuates misinformation.  
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This review suggests that HPV vaccination programmes will have to sufficiently engage with 
local communities before rollout, learning understandings, conceptions and misconceptions, 
language nuances, and perceptions around HPV, the HPV vaccine, and cervical cancer prior 
to proceeding with education and social mobilization around the HPV vaccine. Utilizing local 
language nuances of disease terminology and recognized symptomology may be an important 
consideration for HPV vaccination roll out strategies across SSA, where stakeholders may be 
more likely to understand that the HPV vaccine can curb the perceived symptoms of cervical 
cancer, rather than preventing the disease (cervical cancer) itself (Francis & Katz, 2013; 
Friedman et al., 2014; Katahoire et al., 2008; Nelson et al., 2010; Nyambe et al., 2018; 
Remes et al., 2012). Engagement with and involvement of various social actors such as 
government leaders, religious leaders, HPV vaccination programme leaders, community 
liaisons and community members themselves may facilitate improvements in stakeholder 
perceptions of the HPV vaccine in SSA, especially when mitigating the belief that the HPV 
vaccine causes infertility, a prominent and wide-spread rumor across SSA. Finally, 
implementation of HPV vaccination programmes without thorough understanding of gender 
dynamics within the context of the specific country implementing the vaccine can potentially 
create roadblocks for HPV vaccination uptake, as well as perpetuate confusion, 
misinformation, distrust and stigma. This is notable as this review found that, depending on 
the country, health seeking behavior and decision making around the HPV vaccine was 
driven by either male or female head of households, insinuating that locally appropriate 
interventions need to speak to country specific gender dynamics in health seeking behavior.   
 
Reflexivity  
 
The lead researcher has a background in public health and acknowledges that this has shaped 
positive attitudes towards vaccination more generally. As cervical cancer is largely 
preventable, the lead researcher undertook this analysis in order to better understand extreme 
rates of morbidity and mortality from HPV and cervical cancer in SSA. Preceding the 
literature review, the lead researcher had no expertise in cervical cancer in SSA and upon 
conducting a literature review, had a base-line understanding of theory around cervical 
cancer, HPV, and the HPV vaccine in SSA (Braun & Clarke, 2006). From the protocol to the 
actual review, iterations of the research question (with collaboration with two supervisors) 
narrowed and refined the direction and scope of the research although the crux of the research 
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question remained the same (examining how stakeholders understand the HPV vaccine in 
SSA). The protocol initially stated that a framework will be considered to understand the 
results, but upon doing the actual review, the author decided that the themes in the analysis 
could stand alone (without a framework). Otherwise the protocol was closely adhered to 
when conducting the review. This analysis supports previous research about low levels of 
cervical cancer and HPV vaccine knowledge in SSA, but contributes new and relevant 
knowledge around how stakeholders interpret and understand the HPV vaccine in SSA, an 
under-researched area overall.   
 
Strengths and limitations of the review  
 
A strength of this review is the consideration and acknowledgement of discordant findings 
within the dataset and what such conflicts reveal about understandings of the HPV vaccine in 
SSA. As a systematic review that assesses understandings of the HPV vaccine from a variety 
of stakeholders point of views, all of whom in some way create a demand for the HPV 
vaccine in SSA, has never before been undertaken, the novelty of this review aims to provide 
a ‘big picture’ demand-side perspective to improve current and future HPV vaccination 
strategies in SSA.  
 
Limitations include a single review author for all stages of the search strategy although this 
limitation was addressed through a 20% random sampling of title and abstracts and eligible 
full text studies, assessed by two independent reviewers. A ‘Confidence in Evidence from 
Reviews of Qualitative Research’ was not conducted. The date of studies ranges from 2006-
2018, introducing the possibility that some of the previously published literature is out of date 
compared to present-day. Exclusion of grey literature is a limitation due to time and resource 
constraints, as well as exclusion of non-English studies due to the language capacities of the 
review team.   
 
Conclusion  
 
Stakeholders who create a demand for the HPV vaccine are arguably the most vital to its 
uptake and continued necessity, especially when the momentum of HPV vaccination on the 
continent of Africa has only recently been initiated. How stakeholders understand the HPV 
vaccine will be vital to the short- and long-term success of HPV vaccine programmes. This 
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review found that stakeholder understandings of the HPV vaccine are shaped by a 
dichotomous relationship between HPV vaccine knowledge co-existing with misinformation, 
a significant fear of infertility associated with both cervical cancer diagnosis and the HPV 
vaccine, and social and gender dynamics in SSA. This review iterates the importance of first 
working with communities to gauge local and context-specific understandings, before trying 
to implement change through one-size-fits all education, sensitization and behavior change 
strategies.  
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Part D: Appendices  
 
 
 
Appendix A: Search strategy   
 
PubMed 
("Papillomavirus Vaccines"[Mesh] OR "Human Papillomavirus Recombinant Vaccine 
Quadrivalent, Types 6, 11, 16, 18"[Mesh] 
OR 
“human papillomavirus vaccine” OR “HPV vaccine” OR “human papillomavirus 
vaccination” OR “HPV vaccination” 
AND 
"Health Knowledge, Attitudes, Practice"[Mesh]  
OR 
Knowledge OR attitude OR attitudes OR belief OR beliefs OR perceptions OR perception  
OR comprehend OR comprehension OR experience OR experiences OR understand OR 
understandings OR feel OR feelings OR opinion OR opinions OR point of view OR view OR 
views  
AND 
("Africa"[Mesh] OR "Africa South of the Sahara"[Mesh] OR "Africa, Central"[Mesh] OR 
"Cameroon"[Mesh] OR "Central African Republic"[Mesh] OR "Chad"[Mesh] OR 
"Congo"[Mesh] OR "Democratic Republic of the Congo"[Mesh] OR "Equatorial 
Guinea"[Mesh] OR "Gabon"[Mesh] OR "Sao Tome and Principe"[Mesh] OR "Africa, 
Eastern"[Mesh] OR "Burundi"[Mesh] OR "Djibouti"[Mesh] OR "Eritrea"[Mesh] OR 
"Ethiopia"[Mesh] OR "Kenya"[Mesh] OR "Rwanda"[Mesh] OR "Somalia"[Mesh] OR 
"South Sudan"[Mesh] OR "Sudan"[Mesh] OR "Tanzania"[Mesh] OR "Uganda"[Mesh] OR 
"Africa, Southern"[Mesh] OR "Angola"[Mesh] OR "Botswana"[Mesh] OR "Lesotho"[Mesh] 
OR "Malawi"[Mesh] OR "Mozambique"[Mesh] OR "Namibia"[Mesh] OR "South 
Africa"[Mesh] OR "Swaziland"[Mesh] OR "Zambia"[Mesh] OR "Zimbabwe"[Mesh] OR 
"Africa, Western"[Mesh] OR "Benin"[Mesh] OR "Burkina Faso"[Mesh] OR "Cabo 
Verde"[Mesh] OR "Cote d'Ivoire"[Mesh] OR "Gambia"[Mesh] OR "Ghana"[Mesh] OR 
"Guinea"[Mesh] OR "Guinea-Bissau"[Mesh] OR "Liberia"[Mesh] OR "Mali"[Mesh] OR 
"Mauritania"[Mesh] OR "Niger"[Mesh] OR "Nigeria"[Mesh] OR "Senegal"[Mesh] OR 
"Sierra Leone"[Mesh] OR "Togo"[Mesh]) 
OR 
"Africa" OR "Sub Saharan Africa" OR " Central Africa " OR "Cameroon" OR "Central 
African Republic" OR "Chad" OR "Congo" OR "Democratic Republic of the Congo" OR 
"Equatorial Guinea"  OR "Gabon" OR "Sao Tome and Principe" OR " Eastern Africa " OR 
“East Africa” OR "Burundi" OR "Djibouti" OR "Eritrea" OR "Ethiopia" OR "Kenya" OR 
"Rwanda" OR "Somalia" OR "South Sudan" OR "Sudan" OR "Tanzania" OR "Uganda" OR " 
Southern Africa" OR "Angola" OR "Botswana" OR "Lesotho" OR "Malawi" OR 
"Mozambique" OR "Namibia" OR "South Africa" OR "Swaziland" OR "Zambia" OR 
"Zimbabwe" OR " Western Africa" OR “West Africa” OR "Benin" OR "Burkina Faso" OR 
"Cabo Verde" OR "Cote d'Ivoire" OR "Gambia" OR "Ghana" OR "Guinea" OR "Guinea-
Bissau" OR "Liberia" OR "Mali" OR "Mauritania" OR "Niger" OR "Nigeria" OR "Senegal" 
OR "Sierra Leone" OR "Togo" 
AND  
“Qualitative Research” [Mesh] OR qualitative research OR "Empirical Research" [Mesh] OR 
"Focus Groups" [Mesh] OR "Interviews as Topic"[Mesh] OR "Observational Studies as 
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Topic"[Mesh] OR "Observational Study" [Publication Type]  
OR 
“empirical research” OR interviews OR “focus groups” OR “observational studies” OR 
“thematic analysis” OR Ethnography OR “meta-ethnography” 
 
Other Databases 
EbscoHost (Academic Search Premier, AfricaWide Information, CINAHL, PsychArticles, 
Psychinfo, SocIndex) 
Scopus 
Web of Science 
 
“human papillomavirus vaccine” OR “HPV vaccine” OR “human papillomavirus 
vaccination” OR “HPV vaccination” 
AND 
Knowledge OR attitude OR attitudes OR belief OR beliefs OR perceptions OR perception 
OR comprehend OR comprehension OR experience OR experiences OR understand OR 
understandings OR feel OR feelings OR opinion OR opinions OR point of view OR view OR 
views OR decision OR decisions  
AND 
"Africa" OR "Sub Saharan Africa" OR " Central Africa " OR "Cameroon" OR "Central 
African Republic" OR "Chad" OR "Congo" OR "Democratic Republic of the Congo" OR 
"Equatorial Guinea"  OR "Gabon" OR "Sao Tome and Principe" OR " Eastern Africa " OR 
“East Africa” OR "Burundi" OR "Djibouti" OR "Eritrea" OR "Ethiopia" OR "Kenya" OR 
"Rwanda" OR "Somalia" OR "South Sudan" OR "Sudan" OR "Tanzania" OR "Uganda" OR " 
Southern Africa" OR "Angola" OR "Botswana" OR "Lesotho" OR "Malawi" OR 
"Mozambique" OR "Namibia" OR "South Africa" OR "Swaziland" OR "Zambia" OR 
"Zimbabwe" OR " Western Africa" OR “West Africa” OR "Benin" OR "Burkina Faso" OR 
"Cabo Verde" OR "Cote d'Ivoire" OR "Gambia" OR "Ghana" OR "Guinea" OR "Guinea-
Bissau" OR "Liberia" OR "Mali" OR "Mauritania" OR "Niger" OR "Nigeria" OR "Senegal" 
OR "Sierra Leone" OR "Togo" 
AND  
Qualitative research OR empirical research OR interviews OR focus groups OR 
observational studies OR thematic analysis OR Ethnography OR meta-ethnography  
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Appendix B: Study information log template  
 
Research 
Question 
How do demand-side stakeholders understand the HPV vaccine in SSA? 
Databases to 
search:  
Embase (via Scopus), Scopus, MEDLINE (via PubMed), PubMed, EBSCOhost, Academic 
Search Premier, Africa-Wide Information, CINAHL, PsycARTICLES, PsycINFO, 
SocINDEX, Web of Science, and the Cochrane Controlled Register of Trials (CENTRAL). 
 
First author, 
year  
Study 
Title 
Study 
Locatio
n 
Study 
population 
Data 
type 
Data 
analysis  
Date of 
study 
Authors aim  
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Appendix C: Data extraction template 
 
 
Overarching Theme #1:   
 Transcript 
Quote 
Sub-
theme  
Direct 
participant 
quote from 
analysis  
Sub-
theme  
Secondary 
author 
interpretation 
Sub-
theme  
Reflexivity notes: 
Study          
Study        
Overarching Theme #2 
 Transcript 
Quote 
Sub-
theme  
Direct 
participant 
quote from 
analysis 
Sub-
theme  
Secondary 
author 
interpretation 
Sub-
theme  
Reflexivity notes: 
Study        
Study        
Overarching Theme #3: 
 Transcript 
Quote 
Sub-
theme  
Direct 
participant 
quote from 
analysis 
Sub-
theme  
Secondary 
author 
interpretation 
Sub-
theme  
Reflexivity notes: 
Study        
Study        
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Appendix D: Study information log completed  Key:  
        FGD- Focus group discussion 
        KII- Key informant interview  
        IDI- In depth interview  
        SSI- semi-structured interview  
        ID-SSI- In depth semi-structured interview  
 
 
First author, 
year Title Where Type of stakeholder 
Data 
Collection Data analysis When 
Balogun, 2018 
"She must have 
been sleeping 
around…": 
Contextual 
interpretations of 
cervical cancer and 
views regarding 
HPV vaccination 
for adolescents in 
selected 
communities in 
Ibadan, Nigeria Ibadan, Nigeria 
Parents of adolescents, 
religious and traditional 
leaders, school teachers and 
adolescents, traditional healers FGDs 
Comparative 
case study 
approach to 
conduct 
narrative 
synthesis 2009 
Bingham, 2009 
Sociocultural Issues 
in the Introduction 
of Human 
Papillomavirus 
Vaccine in Low-
Resource Settings 
Uganda (India, 
Peru, Vietnam 
Children, parents, 
teachers/administrators, health 
workers/managers and 
community/religious leaders 
FGDs and 
KIIs 
Comparative 
analysis, table 
matrix 
technique, 
themes 2006-2008 
Crann, 2016 
Healthcare 
providers' 
perspectives on the 
acceptability and 
uptake of HPV 
vaccines in 
Zimbabwe Zimbabwe Health care providers  IDIs 
Thematic 
analysis 2007 
Francis, 2013 
An Analysis of key 
stakeholders' 
attitudes and beliefs 
about barriers and 
facilitating factors 
in the development 
of a cervical cancer 
prevention program 
in South Africa 
South Africa 
(Cape Town and 
Johannesburg) 
Key stakeholders: e.g. 
clinicians, reproductive health 
professionals, educators, 
government officials, 
managers in non-governmental 
organizations, academics, 
infectious disease control 
experts IDIs 
Grounded 
theory and 
thematic 
analysis  2013 
Francis, 2011 
A qualitative 
analysis of South 
African women's 
knowledge, 
attitudes, and 
beliefs about HPV 
and cervical cancer 
prevention, vaccine 
awareness and 
acceptance, and 
maternal-child 
communication 
about sexual health South Africa Women  FGDs 
Grounded 
theory and 
thematic 
analysis Fall 2008 
Friedman, 2014 
Preparing for 
human 
papillomavirus 
vaccine 
introduction in 
Kenya: 
implications from 
focus-group and 
interview 
discussions with 
caregivers and 
opinion leaders in 
Siaya County, 
Kenya 
Caregivers and key informant 
opinion leaders 
FGDs and 
KIIs 
Grounded 
theory method 
through theme 
generation 
July-August 
2012 
  
80 
Western Kenya 
Gallagher, 2018 
The impact of 
human 
papillomavirus 
(HPV) vaccination 
campaign on 
routine primary 
health service 
provision and 
health workers in 
Tanzania: a 
controlled before 
and after study Ibadan, Nigeria Health workers KIIs 
Thematic 
analysis 2014 
Gallagher, 
2018b 
Vaccine 
programme 
stakeholder 
perspectives on a 
hypothetical single-
dose human 
papillomavirus 
(HPV) vaccine 
schedule in low and 
middle-income 
countries 
Data from LMIC: 
Ethiopia, Kenya, 
Lesotho, Nigeria, 
Senegal, Uganda, 
Zambia, 
Zimbabwe, 
country 'z' 
Immunisation managers and 
national immunisation 
technical advisory group 
members  SSIs 
Thematic 
analysis  2017 
Harries, 2009 
Preparing for HPV 
Vaccination in 
South Africa: Key 
challenges and 
opinions 
Western Cape 
Province, South 
Africa 
National and provincial policy 
influential including policy 
makers and managers within 
non-governmental 
organizations, and 
academics/clinicians in the 
field of sexual and 
reproductive health, virology, 
infectious diseases and 
cervical cancer, public sector 
health care providers female 
community members. 
IDIs and 
FGDs 
Content 
analysis and 
thematic 
analysis Feb-07 
Hasahya, 2016 
Beliefs, perceptions 
and health-seeking 
behaviours in 
relation to cervical 
cancer: a qualitative 
study among 
women in Uganda 
following 
completion of an 
HPV vaccination 
campaign 
Nakasongola and 
Ibanda, found in 
central and 
western Uganda 
respectively 
Women aged 25-29 with no 
previous cervical cancer 
symptoms FGDs 
Latent content 
and thematic 
analysis 
Feb-March 
2013 
Yasmine-Isam, 
2018 
Acceptability of the 
two- versus three-
dose human 
papillomavirus 
vaccination 
schedule among 
providers and 
mothers of 
adolescent girls: a 
mixed-methods 
study in five 
countries 
5 LMIC- South 
Africa data 
Mothers of vaccinated and 
unvaccinated adolescent girls FGDs 
Thematic 
analysis 
Nov 2013-
April 2014 
Kamya, 2016 
Evaluating Global 
Health 
Partnerships: A 
Case Study of a 
GAVI HPV 
Vaccine 
Application Process 
in Uganda Kampala, Uganda 
Key informants involved in 
the HPV vaccine application 
process ID-SSIs 
Thematic 
analysis 
Aug-Oct 
2017 
Katahoire, 2013 
Uganda: 
Acceptability of 
HPV Vaccine 
among young 
Ibanda and 
Nakasongola, 
Uganda 
Adolescent girls who have 
completed 3 doses of HPV, 
and partially or non-vaccinated 
girls FGDs 
Thematic 
analysis 2008-2009 
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adolescent girls 
Katehoire, 2008 
An Assessment of 
the Readiness for 
the Introduction of 
the HPV Vaccine in 
Uganda 
Uganda-Gulu in 
the north, Soroti in 
the east, Mbarara 
in the west, and 
Masaka in the 
central region. 
Kampala, the 
capital city, was 
included because 
of its multi-ethnic 
and cosmopolitan 
nature, reflective 
of national 
diversity. 
Children, parents/primary 
caregivers, head 
teachers/teachers, community 
and civic leaders, health 
professionals, district and 
national political and technical 
leaders 
FGDs and 
KIIs 
Thematic 
analysis 2007 
Kisaakye, 2018 
Level and factors 
associated with 
uptake of human 
papillomavirus 
infection 
vaccination among 
female adolescents 
in Lira District, 
Uganda 
Lira District, 
Uganda 
Adolescents and district health 
team members  
IDIs and 
KIIs 
Content 
analysis and 
thematic 
analysis  2016 
Katz, 2013- 
A Qualitative 
Analysis of Factors 
Influencing HPV 
Vaccination Uptake 
in Soweto South 
Africa among 
Adolescents and 
Their Caregivers 
Soweto, South 
Africa Adolescents and caregivers ID-SSIs 
Thematic 
analysis 2010 
Masika, 2015 
Knowledge on the 
HPV Vaccine and 
Cervical Cancer 
Facilitates Vaccine 
Acceptability 
among School 
Teachers in Kitui 
County, Kenya 
Kitui County, 
Kenya Primary school teachers FGDs 
Thematic 
analysis 2013 
Mugisha, 2015 
Feasibility of 
delivering HPV 
vaccine to girls 
aged 10 to 15 years 
in Uganda 
Siaya County, 
Kenya 
Health workers, district 
leaders, and EPI staff 
IDIs and 
FGDs 
Thematic 
analysis 2008-2009 
Nelson, 2010 
Adolescent girls 
who have 
completed 3 doses 
of vaccine, and 
partially or non-
vaccinated girls 
Johannesburg, 
South Africa Traditional healers FGDs 
Grounded 
theory and 
thematic 
analysis  2010 
Nyambe, 2018 
The impact of the 
social environment 
on Zambian 
cervical cancer 
prevention 
practices Zambia 
HCPs, teachers, religious 
leaders, special interest groups 
(advocacy groups and non-
governmental organizations), 
policy makers IDIs 
Thematic 
analysis 
Feb-May 
2016 
Ports, 2013 
Barriers and 
Facilitators to HPV 
Vaccination: 
Perspectives from 
Malawian Women 
Chiradzulu, 
Malawi Mothers  ID-SSI's 
Thematic 
analysis 
Aug-Nov 
2011 
Remes, 2012 
A qualitative study 
of HPV vaccine 
acceptability 
among health 
workers, teachers, 
parents, female 
pupils, and 
religious leaders in 
northwestern 
Mwanza Region, 
Tanzania 
Parents, female pupils, 
teachers, health workers and 
religious leaders 
SSIs and 
FGDs 
Thematic 
analysis 
March-
August 2010 
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Tanzania 
Soi, 2018 
Human 
papillomavirus 
vaccine delivery in 
Mozambique: 
identification of 
implementation 
performance 
drivers using the 
Consolidated 
Framework for 
Implementation 
Research (CFIR) Mozambique 
District health facility 
immunization staff, Ministry 
of Education managers, 
teachers across the three 
demonstration districts, central 
level informants from MOH, 
research institutes, and 
immunization program 
partners. KIIs 
Thematic 
analysis  2018 
Turiho, 2017 
Perceptions of 
human 
papillomavirus 
vaccination of 
adolescent 
schoolgirls in 
western Uganda 
and their 
implications for 
acceptability of the 
HPV vaccination: a 
qualitative study 
Western Uganda, 
Ibanda District 
School girls, 
parents/guardians, school 
teachers, health workers, 
community leaders FGDs 
Thematic 
analysis 
November-
December 
2011 
Turiho, 2014 
Effect of School-
based Human 
Papillomavirus 
(HPV) Vaccination 
of Adolescent Girls' 
Knowledge and 
Acceptability of the 
HPV Vaccine in 
Ibanda District in 
Uganda 
Ibanda District 
Uganda Adolescent girls FGDS 
Thematic 
analysis 
November-
December 
2012 
Venturas, 2017 
Health professional 
feedback on HPV 
vaccination roll-out 
in a developing 
country Zambia Health professionals  SSIs  
Thematic 
analysis 2017 
Vermandere, 
2016 
Introduction of 
HPV vaccination in 
Kenya Kenya 
Fathers, adolescents, teachers 
and vaccinators, school 
teachers, health workers and 
community leaders. 
FGDs and 
KIIs 
Thematic 
analysis 
May 2012- 
March 2013 
Vermandere, 
2015 
Implementation of 
an HPV vaccination 
program in Eldoret, 
Kenya: results from 
a qualitative 
assessment by key 
stakeholders Eldoret, Kenya Teachers, fathers, vaccinators FGDs 
Thematic 
analysis 
May 2012-
March 2013 
Vielot, 2017 
Acceptability of 
multipurpose 
human 
papillomavirus 
vaccines among 
providers and 
adolescent girls: A 
mixed-methods 
study in five 
countries 
5 geographically 
diverse countries- 
South Africa data Mothers FGDs 
Thematic 
analysis 
Nov 2013-
April 2014 
Watson-Jones, 
2015 
Access and 
Attitudes to HPV 
Vaccination 
amongst Hard-To-
Reach Populations 
in Kenya Nairobi, Kenya 
Ministry of health and 
education personnel, 
community and religious 
leaders, teachers, parents, girls 
and boys FGDs 
Thematic 
analysis 
Nov 2012-
Feb 2013 
Watson-Jones, 
2016 
Feasibility and 
acceptability of 
delivering 
adolescent health Tanzania 
Health and education policy 
makers and district officials KIIs 
Thematic 
analysis 2013 
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interventions 
alongside HPV 
vaccination in 
Tanzania 
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Appendix E: Critical Appraisal Skills Programme Checklist  
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Appendix F: CASP appraisal outcomes by study  
 
 
 Section A: Are results valid? Section B: What 
are the results? 
 Section C: Will 
the results help 
locally? 
Author, year Was there 
a clear 
statement 
of the 
aims of 
the 
research? 
Is a qualitative 
methodology 
appropriate?  
Was the 
research design 
appropriate to 
address the 
aims of the 
research? 
Was the 
recruitment 
statement 
appropriate to 
the aims of the 
research? 
Was the data 
collected in a 
way that 
addressed the 
research 
issue? 
Has the 
relationship 
between 
researcher and 
participants 
been adequately 
considered? 
Have ethnical 
issues been taken 
into consideration? 
Was the data 
analysis 
sufficiently 
rigourous? 
Is there a clear 
statement of 
findings? 
How valuable 
is the research? 
Balogun, 2018 Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes 
Bingham, 2009 Yes Yes Yes Yes Yes No Yes Can’t tell Yes Can’t tell  
Crann, 2016 Yes Yes Yes Yes Yes Can’t tell  Yes Yes Yes Yes 
Francis, 2011 Yes Yes Yes Yes Yes Yes No Yes Yes Can’t tell  
Francis, 2013 Yes Yes Yes Yes Yes No Can’t tell No  Can’t tell  Yes 
Friedman, 2014 Yes Yes Yes Yes Yes No Can’t tell Can’t tell No Yes 
Gallagher, 2018 Yes Yes Yes Yes Yes No Can’t tell Can’t tell Yes Yes 
Gallagher, 2018b Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes 
Harries, 2009 Yes Yes Yes Yes Yes Yes Can’t tell Yes Can’t tell  Yes 
Hasahya, 2016 Yes Yes Yes Yes Yes Can’t tell  Yes Can’t tell Can’t tell  Can’t tell  
Kamya, 2017 Yes Yes Yes Yes Yes Yes No No Yes Yes 
Katahoire, 2008 Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes 
Katahoire, 2013 Yes Yes Yes Yes Yes No Yes Can’t tell Yes Yes 
Katz, 2013 Yes Yes Yes Yes Yes No Yes Can’t tell No Yes 
Kisaakye, 2018 Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes 
Masika, 2015 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Mugisha, 2015 Yes Yes Yes Yes Yes Yes No No Yes Yes 
Nelson 2010 Yes Yes Yes Yes Yes Can’t tell Yes No Yes Yes 
Nambe 2018 Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes 
Ports, 2013 Yes Yes Yes Yes Yes Yes Yes No Yes Yes 
Remes, 2012  Yes Yes Yes Yes Yes Yes Yes No Can’t tell  Can’t tell  
Soi, 2018 Yes Yes Yes Yes Yes Can’t tell No Yes Yes Yes 
Tuhiro, 2014 Yes Yes Yes Yes Yes Yes No Can’t tell Yes Yes 
Tuhiro, 2017  Yes Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes 
Venturas, 2017 Yes Yes Yes Yes Yes Can’t tell  Can’t tell Ye Yes Yes 
Vermandere, 2015 Yes Yes Yes Yes Yes Can’t tell  Can’t tell Yes Yes Yes 
Vermandere, 2016 Yes Yes Yes Yes Yes Yes Can’t tell Can’t tell Yes Yes 
Vielot, 2017 Yes Yes Yes Yes Yes No Yes Cant tell Yes Yes 
Watson-Jones, 2016 Yes Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes 
Watson-Jones, 2015 Yes Yes Yes Yes Yes Can’t tell Yes Yes Yes Yes 
Yasmine Islam, 2018 Yes Yes Yes Yes Yes No Yes  Yes Yes Yes 
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Appendix G: Evidence for themes by study  
 
Major 
themes  
Theme 1: Knowledge about HPV vaccine intertwined with misinformation  Theme 2: Fear Shaping contradictory perceptions of 
the HPV Vaccine 
Theme 3: Social norms and 
gender dynamics influence on 
understandings of the HPV 
vaccine in SSA 
Sub-themes  Levels of 
Technical 
knowledge  
Willingness to 
learn about 
HPV vaccine 
Different 
perceptions of 
causes of 
cervical cancer  
Risk 
perception of 
HPV and 
cervical 
cancer  
Language and 
symptomology in 
HPV/cervical 
cancer 
understandings  
Misinformation  Fear of 
cervical 
cancer  
Fear that 
cervical 
cancer 
causes 
infertility  
Fear that the 
HPV 
vaccine 
causes 
infertility  
Distrust of 
HPV 
vaccine 
initiatives  
Social 
influence on 
perceptions of 
HPV vaccine 
Gendered 
dynamic 
affecting 
perceptions of 
HPV vaccines 
Balogun, 
2018 
✓ 
 
 ✓ 
 
✓ 
 
 ✓ 
 
✓ 
 
 ✓ 
 
   
Bingham, 
2009 
    ✓ 
 
    ✓ 
 
  
Crann, 2016 ✓ 
 
   ✓ 
 
✓ 
 
  ✓ 
 
 ✓ 
 
✓ 
 
Francis, 2011 ✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
 ✓ 
 
    ✓ 
 
Francis, 2013    ✓ 
 
✓ 
 
 ✓ 
 
✓ 
 
✓ 
 
  ✓ 
 
Friedman, 
2014 
    ✓ 
 
✓ 
 
✓ 
 
 
✓ 
 
 ✓ 
 
 ✓ 
 
Gallagher, 
2018 
            
Gallagher, 
2018b 
            
Harries, 2009 ✓ 
 
  ✓ 
 
✓ 
 
✓ 
 
 ✓ 
 
 ✓ 
 
 ✓ 
 
Hasahya, 
2016 
   ✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
   
Kamya, 2017             
Katahoire, 
2008 
   ✓ 
 
✓ 
 
      ✓ 
 
Katahoire, 
2013 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
 
✓ 
 
 ✓ 
 
✓ 
 
 ✓ 
 
✓ 
 
Katz, 2013           ✓ 
 
✓ 
 
Kisaakye, 
2018 
✓ 
 
    ✓ 
 
      
Masika, 2015   ✓ 
 
  ✓ 
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Mugisha, 
2015 
            
Nelson 2010    ✓ 
 
✓ 
 
      ✓ 
 
Nyambe 
2018 
  ✓ 
 
 ✓ 
 
✓ 
 
 ✓ 
 
 ✓ 
 
✓ 
 
✓ 
 
Ports, 2013 ✓ 
 
 ✓ 
 
✓ 
 
✓ 
 
      ✓ 
 
Remes, 2012  ✓ 
 
 ✓ 
 
✓ ✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
✓ 
 
Soi, 2018      ✓ 
 
 ✓ 
 
✓ 
 
  ✓ 
 
Tuhiro, 2014 ✓ 
 
  ✓ 
 
   ✓ 
 
✓ 
 
   
Tuhiro, 2017    ✓ 
 
  ✓ 
 
✓ 
 
 ✓ 
 
✓ 
 
✓ 
 
✓ 
 
Venturas, 
2017 
    ✓ 
 
✓ 
 
 ✓ 
 
✓ 
 
✓ 
 
 ✓ 
 
Vermandere, 
2015 
  ✓ 
 
✓ 
 
✓ 
 
      ✓ 
 
Vermandere, 
2016 
✓ 
 
 ✓ 
 
  ✓ 
 
  ✓ 
 
 ✓ 
 
 
Vielot, 2017  ✓ 
 
    ✓ 
 
     
Watson-
Jones, 2016 
        ✓ 
 
  ✓ 
 
Watson-
Jones, 2015 
✓ 
 
      ✓ 
 
 ✓ 
 
✓ 
 
 
Islam, 2018      ✓ 
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